AGREEMENT AND PLAN OF MERGER by and among OPTO CIRCUITS (INDIA) LTD., JOLT ACQUISITION COMPANY, and CARDIAC SCIENCE CORPORATION October 19, 2010
Exhibit 2.1
AGREEMENT AND PLAN OF MERGER
by and among
OPTO CIRCUITS (INDIA) LTD.,
JOLT ACQUISITION COMPANY,
and
CARDIAC SCIENCE CORPORATION
October 19, 2010
TABLE OF CONTENTS
Page | ||||
ARTICLE I DEFINITIONS AND TERMS |
2 | |||
Section 1.1 Definitions |
2 | |||
Section 1.2 Other Definitional Provisions; Interpretation |
9 | |||
ARTICLE II THE OFFER |
9 | |||
Section 2.1 The Offer |
9 | |||
Section 2.2 Top-Up Option |
12 | |||
Section 2.3 Company Actions |
13 | |||
Section 2.4 Directors |
15 | |||
ARTICLE III THE MERGER |
16 | |||
Section 3.1 The Merger |
16 | |||
Section 3.2 Effective Time |
16 | |||
Section 3.3 Closing |
16 | |||
Section 3.4 Certificate of Incorporation and Bylaws of the Surviving Corporation |
16 | |||
Section 3.5 Directors and Officers of the Surviving Corporation |
17 | |||
ARTICLE IV CONVERSION OF SHARES |
17 | |||
Section 4.1 Conversion of Shares |
17 | |||
Section 4.2 Exchange of Certificates and Book-Entry Shares |
18 | |||
Section 4.3 Shares of Dissenting Stockholders |
19 | |||
Section 4.4 Treatment of Stock Awards; ESPP |
20 | |||
ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE COMPANY |
21 | |||
Section 5.1 Organization |
21 | |||
Section 5.2 Capitalization |
21 | |||
Section 5.3 Authorization; Validity of Agreement; Company Action |
22 | |||
Section 5.4 Consents and Approvals; No Violations |
23 | |||
Section 5.5 SEC Reports; Disclosure Controls |
23 | |||
Section 5.6 No Undisclosed Liabilities |
24 | |||
Section 5.7 Material Contracts |
24 | |||
Section 5.8 Employee Benefit Plans; ERISA |
25 | |||
Section 5.9 Litigation |
26 | |||
Section 5.10 Compliance with Law |
27 | |||
Section 5.11 Intellectual Property |
27 | |||
Section 5.12 Taxes |
28 | |||
Section 5.13 Assets and Properties |
29 | |||
Section 5.14 Environmental |
29 | |||
Section 5.15 Labor Matters |
29 | |||
Section 5.16 FDA Regulatory Compliance |
30 | |||
Section 5.17 Proxy Statement |
31 | |||
Section 5.18 Brokers or Finders |
31 |
i
TABLE OF CONTENTS
(continued)
(continued)
Page | ||||
Section 5.19 Stockholders’ Rights Agreement |
31 | |||
Section 5.20 State Takeover Statutes |
31 | |||
Section 5.21 Insurance |
32 | |||
Section 5.22 Related Party Transactions |
32 | |||
Section 5.23 Inventory |
32 | |||
Section 5.24 Accounts Receivable |
32 | |||
Section 5.25 Ethical Practices |
32 | |||
ARTICLE VI REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB |
32 | |||
Section 6.1 Organization |
32 | |||
Section 6.2 Authorization; Validity of Agreement; Necessary Action |
33 | |||
Section 6.3 Consents and Approvals; No Violations |
33 | |||
Section 6.4 Litigation |
34 | |||
Section 6.5 Ownership of Capital Stock |
34 | |||
Section 6.6 Compliance with Law |
34 | |||
Section 6.7 Merger Sub’s Operations |
34 | |||
Section 6.8 Proxy Statement |
34 | |||
Section 6.9 Sufficient Funds |
34 | |||
Section 6.10 Brokers or Finders |
34 | |||
ARTICLE VII COVENANTS |
34 | |||
Section 7.1 Interim Operations of the Company |
34 | |||
Section 7.2 Access to Information |
36 | |||
Section 7.3 Acquisition Proposals |
36 | |||
Section 7.4 Employee Benefits |
38 | |||
Section 7.5 Publicity |
39 | |||
Section 7.6 Directors’ and Officers’ Insurance and Indemnification |
39 | |||
Section 7.7 Proxy Statement; Stockholders Meeting |
40 | |||
Section 7.8 Best Efforts |
41 | |||
Section 7.9 No Control of Other Party’s Business |
42 | |||
Section 7.10 Rule 14d-10 Matters |
42 | |||
Section 7.11 Rule 16b-3 |
42 | |||
Section 7.12 Delisting |
42 | |||
Section 7.13 Withholding |
43 | |||
Section 7.14 Transfer Taxes |
43 | |||
ARTICLE VIII CONDITIONS |
43 | |||
Section 8.1 Conditions to Each Party’s Obligation to Effect the Merger |
43 | |||
Section 8.2 Frustration of Closing Conditions |
43 | |||
ARTICLE IX TERMINATION |
44 | |||
Section 9.1 Termination |
44 | |||
Section 9.2 Effect of Termination |
45 |
ii
TABLE OF CONTENTS
(continued)
(continued)
Page | ||||
ARTICLE X MISCELLANEOUS |
46 | |||
Section 10.1 Amendment and Modification |
46 | |||
Section 10.2 Nonsurvival of Representations and Warranties |
46 | |||
Section 10.3 Notices |
46 | |||
Section 10.4 Interpretation |
48 | |||
Section 10.5 Counterparts |
48 | |||
Section 10.6 Entire Agreement; Third-Party Beneficiaries |
48 | |||
Section 10.7 Severability |
48 | |||
Section 10.8 Governing Law; Venue |
48 | |||
Section 10.9 Specific Performance |
49 | |||
Section 10.10 Assignment |
49 | |||
Section 10.11 Expenses |
49 | |||
Section 10.12 Headings |
49 | |||
Section 10.13 Waivers |
49 | |||
Section 10.14 Waiver of Jury Trial |
49 |
Exhibit A
|
Offer Conditions | |
Exhibit B
|
Form of Certificate of Merger | |
Exhibit C
|
Form of Amended and Restated Certificate of Incorporation of the Surviving Corporation |
iii
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT AND PLAN OF
MERGER is entered into as of 12:01 a.m. Pacific Time on
October 19, 2010 (this
“Agreement”) by and among Cardiac Science Corporation, a Delaware corporation (the
“Company”), Opto Circuits (India) Ltd., a public limited company incorporated under the
laws of the nation of India (“Parent”), and Jolt Acquisition Company, a Delaware
corporation and wholly-owned subsidiary of Parent (“Merger Sub”).
WHEREAS, Parent desires to acquire the Company on the terms and subject to the conditions set
forth in this Agreement;
WHEREAS, in furtherance of the acquisition of the Company by Parent, Parent proposes to cause
Merger Sub to commence an offer (as it may be amended from time to time as permitted under this
Agreement, the “Offer”) to purchase all of the outstanding shares of common stock, par
value $0.001 per share, of the Company (the “Common Stock”) at a price per share of Common
Stock of $2.30, net to the seller in cash, without interest (the “Offer Price”), upon the
terms and subject to the conditions set forth in this Agreement;
WHEREAS, it is proposed that, on the terms and subject to the conditions set forth in this
Agreement, following the consummation of the Offer, Merger Sub shall, in accordance with the DGCL,
merge with and into the Company (the “Merger”), pursuant to which each share of Common
Stock, other than (i) shares of Common Stock directly or indirectly owned by Parent, Merger Sub or
the Company and (ii) Dissenting Shares, will be converted into the right to receive the Merger
Consideration;
WHEREAS, the board of directors of the Company (the “Company Board”) has unanimously
(a) determined that the Offer, the Merger and the other transactions contemplated hereby
(collectively, the “Transactions”), are advisable, fair to and in the best interests of the
stockholders of the Company, (b) adopted and approved this Agreement and the Transactions and
declared it advisable that the Company enter into this Agreement and consummate the Transactions,
(c) resolved to recommend that the Company’s stockholders accept the Offer and approve the Merger
and (d) approved taking all actions so that the restrictions on “business combinations” set forth
in Section 203 of the DGCL (the “Delaware Takeover Statute”) and the restrictions on
“significant business transactions” set forth in Chapter 23B.19 of the Washington Business
Corporation Act (the “Washington Takeover Statute”) will not apply to the execution,
delivery or performance of this Agreement, or to the consummation of the Transactions, including
the Offer and Merger;
WHEREAS, the board of directors of Merger Sub has adopted, approved and declared it advisable
for Merger Sub to enter into this Agreement and to consummate the Transactions upon the terms and
subject to the conditions set forth herein;
WHEREAS, the board of directors of Parent has approved this Agreement and the Transactions,
and Parent, in its capacity as the sole stockholder of Merger Sub, has adopted and approved this
Agreement and the Transactions upon the terms and subject to the conditions set forth herein;
NOW, THEREFORE, in consideration of the foregoing and the representations, warranties,
covenants and agreements set forth herein, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound
hereby, agree as follows:
ARTICLE I
DEFINITIONS AND TERMS
DEFINITIONS AND TERMS
Section 1.1 Definitions. As used in this Agreement, the following terms have the
meanings set forth below:
“Acceptable Confidentiality Agreement” has the meaning set forth in Section
7.3(b).
“Acquisition Agreement” has the meaning set forth in Section 7.3(c).
“Acquisition Proposal” means any written inquiry, proposal or offer made by any
Person, Persons or group of Persons other than Parent, Merger Sub or any Affiliate thereof relating
to (a) the acquisition, other than in the Transactions, of the beneficial ownership (as defined
under Section 13(d) of the Exchange Act) of fifteen percent (15%) or more of the Common Stock, (b)
any merger, consolidation, business combination, reorganization, share exchange or similar
transaction involving the Company, (c) any sale of assets, license (other than any non-exclusive
license entered into in the ordinary course of business), joint venture, liquidation, dissolution,
disposition, merger, consolidation or other transaction which would, directly or indirectly, result
in any Person or Persons other than Parent, Merger Sub or any Affiliate thereof acquiring or
licensing assets (including equity interests of any Subsidiary of the Company) representing
directly or indirectly, fifteen percent (15%) or more of the net revenues, net income or assets (in
the case of assets, determined by reference to book value or fair market value) of the Company and
its Subsidiaries, taken as a whole, (d) any tender offer or exchange offer, as such terms are
defined under the Exchange Act, or other transaction that, if consummated, would result in any
Person other than Parent, Merger Sub or any Affiliate thereof beneficially owning more than fifteen
percent (15%) of the Common Stock or (e) any combination of the foregoing.
“Affiliate” has the meaning set forth in Rule 12b-2 of the Exchange Act.
“Agreement” has the meaning set forth in the Preamble.
“Benefit Agreement” has the meaning set forth in Section 5.8(a).
“Benefit Plan” has the meaning set forth in Section 5.8(a).
“Book-Entry Shares” has the meaning set forth in Section 4.1(d).
“Business Day” means a day
other than a Saturday, a Sunday or another day (excluding Election
Day) on which
commercial banking institutions in New York, New York are authorized or required by Law to be
closed.
“Certificate of Merger” has the meaning set forth in Section 3.2.
“Certificates” has the meaning set forth in Section 4.1(d).
“cGMP” has the meaning set forth in Section 5.16(a).
“Change of Recommendation” has the meaning set forth in Section 7.3(c).
“CIC Plans” has the meaning set forth in Section 7.4(b).
“Cleanup” means all actions required, under applicable Environmental Laws, to
investigate, clean up, remove, treat or remediate Hazardous Materials.
2
“Closing” has the meaning set forth in Section 3.3.
“Closing Date” has the meaning set forth in Section 3.3.
“Code” means the Internal Revenue Code of 1986, as amended.
“Common Stock” has the meaning set forth in the Recitals.
“Company” has the meaning set forth in the Preamble.
“Company Board” has the meaning set forth in the Recitals.
“Company Disclosure Schedule” means the final disclosure schedule delivered by the
Company to Parent immediately prior to the execution of this Agreement.
“Company Equity Plans” means the Company’s 1997 Stock Option/Stock Issuance Plan, as
amended, 2002 Stock Incentive Plan, as amended, the ESPP, as amended, and the Xxxxxxx Cardiology
Systems, Inc. 1998 Amended and Restated Equity Incentive Plan.
“Company Material Adverse Effect” means any change which has a material adverse effect
on (a) the business, financial condition or continuing operations of the Company and its
Subsidiaries, taken as a whole or (b) the ability of the Company to consummate the Transactions;
provided, however, that none of the following shall constitute or be taken into consideration in
determining whether there has occurred, and no change, event, occurrence or effect resulting from,
attributable to or arising out of any of the following shall constitute, a Company Material Adverse
Effect:
(i) changes generally affecting (A) the industries and markets in which the Company and
its Subsidiaries operate, (B) the U.S. economy or (C) the U.S. securities markets,
(ii) the negotiation, execution, announcement or performance of this Agreement and the
consummation of the Transactions (including any cancellation of or delays in customer orders
or work for clients, any reductions in sales, any disruption in licensor, vendor, partner or
similar relationships or any loss of employees arising out of such negotiations, execution,
announcement, performance or consummation),
(iii) natural disasters, acts of war, terrorism or sabotage, military actions or the
escalation thereof or other force majeure events,
(iv) changes in GAAP or changes in the interpretation of GAAP, or changes in the
accounting rules and regulations of the SEC,
(v) any other action required by Law, expressly contemplated by this Agreement or taken
at the request of or with the written consent of Parent or Merger Sub,
(vi) any changes in Law or the interpretation thereof that do not have a materially
disproportionate and adverse impact on the Company or its business in relation to other
companies in the Company’s industry,
(vii) any litigation brought or threatened with respect to the Transactions by
stockholders of either the Company or Parent (whether on behalf of the Company, Parent or
otherwise) asserting allegations of breach of fiduciary duty or violations of securities
Laws,
3
(viii) any action required to comply with the rules and regulations of the SEC or the
SEC comment process, in each case, in connection with Schedule 14D-9 or the Proxy Statement,
(ix) in and of itself, any decrease in the market price or trading volume of the Common
Stock, or
(x) in and of itself, any failure by the Company to meet any projections, forecasts or
revenue or earnings predictions, or any predictions or expectations of any securities
analysts.
“Company Recommendation” has the meaning set forth in Section 7.7(a).
“Company SEC Reports” has the meaning set forth in Section 5.5(a).
“Company Stockholders Meeting” has the meaning set forth in Section 7.7(a).
“Company Termination Fee” has the meaning set forth in Section 9.2(b).
“Consideration Fund” has the meaning set forth in Section 4.2(a).
“Continuing Director” has the meaning set forth in Section 2.4(c).
“Contract” means any note, bond, mortgage, indenture, lease, license, contract,
agreement or other consensual obligation.
“Current Purchase Period” has the meaning set forth in Section 4.4(d).
“Delaware Takeover Statute” has the meaning set forth in the Recitals.
“Delisting Period” has the meaning set forth in Section 7.12.
“DGCL” means the Delaware General Corporation Law.
“Dissenting Shares” has the meaning set forth in Section 4.3(a).
“Effective Time” has the meaning set forth in Section 3.2.
“Employees” has the meaning set forth in Section 7.4(a).
“Environmental Claim” means any claim, notice, directive, action, cause of action,
investigation, suit, demand, abatement order or other order by a Governmental Entity alleging
liability arising out of, based on, or resulting from (a) the release of any Hazardous Materials at
any location or (b) circumstances forming the basis of any violation of any Environmental Law.
“Environmental Laws” means all applicable and legally enforceable Laws relating to
pollution or protection of the environment, including Laws relating to releases of Hazardous
Materials and the manufacture, processing, distribution, use, treatment, storage, release,
transport, disposal, recycling or handling of Hazardous Materials.
“ERISA” has the meaning set forth in Section 5.8(a).
“ESPP” means the Company’s 2002 Employee Stock Purchase Plan.
4
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
“Expiration Date” has the meaning set forth in Exhibit A.
“Fairness Opinion” has the meaning set forth in Section 5.3(c).
“FDA” means the U.S. Food and Drug Administration.
“FDCA” has the meaning set forth in Section 5.16(a).
“GAAP” has the meaning set forth in Section 5.5(a).
“Governmental Entity” has the meaning set forth in Section 5.4.
“Hazardous Materials” means all substances defined as Hazardous Substances, Oils,
Pollutants or Contaminants in the National Oil and Hazardous Substances Pollution Contingency Plan,
40 C.F.R. § 300.5, or defined as such by, or regulated as such under, any Environmental Law.
“HSR Act” means the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act of 1976, as amended.
“Indemnified Parties” has the meaning set forth in Section 7.6(a).
“Insured Parties” has the meaning set forth in Section 7.6(b).
“Intellectual Property” means all rights in patents and patent applications,
trademarks and service marks (whether registered or not) and the goodwill of the business in
connection therewith, trademark applications, service xxxx registrations and service xxxx
applications, trade names, trade dress, logos, slogans, tag lines, uniform resource locators,
Internet domain names, Internet domain name applications, corporate names, copyright applications,
registered copyrighted works and commercially significant unregistered copyrightable works
(including proprietary software), technology, software, trade secrets, know-how, technical
documentation, specifications, data, designs and other intellectual property and proprietary
rights, other than off-the-shelf computer programs, and the right to xxx for past infringement of
all such rights.
“In the Money Option” has the meaning set forth in Section 4.4(a).
“IRS” means the U.S. Internal Revenue Service.
“knowledge” means such facts and other information that as of the date of
determination are actually known to, in the case of the Company, the Company’s chief executive
officer, chief financial officer, general counsel and the individuals set forth in Section
1.1(a) of the Company Disclosure Schedule, and in the case of Parent or Merger Sub, the
individuals set forth on Schedule 1.1(b) of the Parent Disclosure Schedule.
“Law” means any federal, state, local or foreign law, statute, ordinance, regulation,
judgment, order, decree, injunction, arbitration award, franchise, license, agency requirement or
permit of any Governmental Entity.
“Leased Real Property” means all leasehold or subleasehold estates and other rights to
use or occupy any land, buildings, structures, improvements, fixtures or other interest in real
property held by the Company or any of its Subsidiaries.
5
“Leases” means all binding leases, subleases, licenses, concessions and other
agreements pursuant to which the Company or any of its Subsidiaries holds any Leased Real Property,
including the right to all security deposits and other amounts or instruments deposited by on
behalf of the Company or any of its Subsidiaries thereunder.
“License-In Agreements” has the meaning set forth in Section 5.11(b).
“Material Contract” has the meaning set forth in Section 5.7(a).
“Medical Device” has the meaning set forth in Section 5.16(a).
“Merger” has the meaning set forth in the Recitals.
“Merger Consideration” has the meaning set forth in Section 4.1(a).
“Merger Sub” has the meaning set forth in the Preamble.
“Minimum Tender Condition” has the meaning set forth in Exhibit A.
“Nasdaq” has the meaning set forth in Section 2.1(a)(ii).
“Nasdaq Marketplace Rules” shall mean the rules concerning Nasdaq-listed companies
promulgated by Nasdaq from time to time and published in the Nasdaq Manual Online located at
xxx.xxxxxx.xxx.
“Non-Disclosure Agreement” has the meaning set forth in Section 7.2.
“Offer” has the meaning set forth in the Recitals.
“Offer Closing” has the meaning set forth in Section 2.1(a)(iii).
“Offer Closing Date” has the meaning set forth in Section 2.1(a)(iii).
“Offer Conditions” has the meaning set forth in Section 2.1(a).
“Offer Documents” has the meaning set forth in Section 2.1(b).
“Offer Price” has the meaning set forth in the Recitals.
“Option” has the meaning set forth in Section 4.4(a).
“Option Consideration” has the meaning set forth in Section 4.4(a).
“Parent” has the meaning set forth in the Preamble.
“Parent Disclosure Schedule” means the final disclosure schedule delivered by Parent
to the Company immediately prior to the execution of this Agreement.
“Parent Material Adverse Effect” means any change which would have a material
adverse effect on (a) the business, financial condition or operations of Parent and its
Subsidiaries, taken as a whole or (b) the ability of Parent or Merger Sub to consummate the
Transactions (including Parent’s absolute obligation to have sufficient funds to satisfy its
obligations to pay the aggregate Merger Consideration,
6
Option Consideration and RSU Consideration and other fees and expenses of Parent and Merger
Sub); provided, however, that none of the following shall constitute or be taken into consideration
in determining whether there has occurred, and no change, event, occurrence or effect resulting
from, attributable to or arising out of any of the following shall constitute, a Parent Material
Adverse Effect:
(i) changes generally affecting (a) the industries and markets in which Parent and its
Subsidiaries operate, (b) the U.S. economy or (c) the U.S. securities markets;
(ii) the negotiation, execution, announcement or performance of this Agreement and the
consummation of the Transactions (including any cancellation of or delays in customer orders
or work for clients, any reductions in sales, any disruption in licensor, vendor, partner or
similar relationships or any loss of employees arising out of such negotiations, execution,
announcement, performance or consummation),
(iii) natural disasters, acts of war, terrorism or sabotage, military actions or the
escalation thereof or other force majeure events,
(iv) changes in GAAP or changes in the interpretation of GAAP, or changes in the
accounting rules and regulations of the SEC,
(v) any other action required by Law, expressly contemplated by this Agreement or taken
at the request of or with the written consent of the Company,
(vi) any changes in Law or the interpretation thereof which do not have a materially
disproportionate and adverse impact on Parent in relation to other companies in Parent’s
industry,
(vii) any litigation brought or threatened with respect to the Transactions by
stockholders of either the Company or Parent (whether on behalf of the Company, Parent or
otherwise) asserting allegations of breach of fiduciary duty or violations of securities
Laws, or
(viii) any action required to comply with the rules and regulations of the SEC or the
SEC comment process, in each case, in connection with the Offer Documents or the Proxy
Statement.
“Parent Plans” has the meaning set forth in Section 7.4(c).
“Parent Termination Fee” has the meaning set forth in Section 9.2(c).
“Paying Agent” has the meaning set forth in Section 4.2(a).
“PBGC” has the meaning set forth in Section 5.8(f).
“Permits” means all governmental approvals, authorizations, licenses, orders,
registrations, permits, product qualifications, and certificates of all agencies, whether federal,
state, local or foreign.
“Permitted Liens” means liens granted to third parties in the ordinary course of
business.
“Person” means any natural person or any corporation, partnership, limited liability
company, association, trust or other entity or organization, including any Governmental Entity.
“Post-Closing SEC Reports” has the meaning set forth in Section 7.12.
“Proxy Statement” has the meaning set forth in Section 7.7.
7
“Representatives” has the meaning set forth in Section 2.1(b).
“Required Company Stockholder Vote” has the meaning set forth in Section
5.3(a).
“RSU” has the meaning set forth in Section 4.4(b).
“RSU Consideration” has the meaning set forth in Section 4.4(b).
“Schedule 14D-9” has the meaning set forth in Section 2.3(b).
“Schedule TO” has the meaning set forth in Section 2.1(b).
“SEC” means the U.S. Securities and Exchange Commission.
“Securities Act” means the Securities Act of 1933, as amended.
“Short-Form Threshold” has the meaning set forth in Section 7.7(c).
“Subsidiary” means, as to any Person, any corporation, partnership, limited liability
company, association or other business entity (a) of which such Person directly or indirectly owns
securities or other equity interests representing more than fifty percent (50%) of the aggregate
voting power, (b) of which such Person possesses more than fifty percent (50%) of the right to
elect directors or Persons holding similar positions, or (c) that such Person controls directly or
indirectly through one or more intermediaries.
“Superior Proposal” means any Acquisition Proposal (with all of the percentages in the
definition of Acquisition Proposal increased to fifty-one percent (51%)) that the Company Board
determines, after consultation with its financial advisor and outside counsel, in its good faith
judgment is reasonably likely to be consummated in accordance with its terms, taking into account
all legal, financial and regulatory aspects of the Acquisition Proposal and this Agreement, and if
consummated, would result in a transaction more favorable to the Company’s stockholders from a
financial point of view than the Transactions (in each case taking into account any revisions to
this Agreement made or proposed in writing by Parent).
“Surviving Corporation” has the meaning set forth in Section 3.1.
“Tax Return” means any return, report, declaration, estimate, or statement required to
be filed with respect to any Tax (including any schedules and attachments thereto), including any
information return, claim for refund, amended return or declaration of estimated Tax.
“Tax or Taxes” means all taxes, charges, fees, levies, duties, or other assessments or
charges of any kind whatsoever, including, without limitation, all federal, state, city, county,
and non-U.S. (or governmental unit, agency, or political subdivision of any of the foregoing)
income (net, gross, or other), profits, employment (including Social Security, unemployment, and
employee income tax withholding), franchise, gross receipts, net worth, sales, use, service,
service use, occupation, ad valorem, transfer, recording, license, withholding, payroll, estimated,
severance, stamp, real property, personal property, or other taxes, customs, value added and excise
taxes, including all interest and penalties thereon, whether disputed or not, and including any
obligation to indemnify or otherwise assume or succeed to the Tax Liability of any other Person,
whether by contract or otherwise, and additions to tax or additional amounts imposed by any
Governmental Entity upon the Company or its Subsidiaries.
8
“Tender Offer Statement” has the meaning set forth in Section 2.1(b).
“Termination Date” has the meaning set forth in Section 9.1(b)(i).
“Top-Up Option” has the meaning set forth in Section 2.2(a).
“Top-Up Option Shares” has the meaning set forth in Section 2.2(a).
“Transactions”
has the meaning set forth in the Recitals.
“U.S.”
means the United States of America.
“Washington Takeover Statute” has the meaning set forth in the Recitals.
Section 1.2 Other Definitional Provisions; Interpretation.
(a) The words “hereof,” “herein” and words of similar import shall, unless otherwise stated,
be construed to refer to this Agreement as a whole and not to any particular provision of this
Agreement, and references to articles, sections, paragraphs, exhibits and schedules are to the
articles, sections and paragraphs of, and exhibits and schedules to, this Agreement, unless
otherwise specified.
(b) Whenever “include,” “includes” or “including” is used in this Agreement, such word shall
be deemed to be followed by the phrase “without limitation.”
(c) Words describing the singular number shall be deemed to include the plural and vice versa,
words denoting any gender shall be deemed to include all genders and words denoting natural persons
shall be deemed to include business entities and vice versa.
(d) When used in reference to information or documents, the phrase “made available” means that
the information or documents referred to have been made available if requested by the party to
which such information or documents are to be made available.
(e) Terms defined in the text of this Agreement as having a particular meaning have such
meaning throughout this Agreement, except as otherwise indicated in this Agreement.
ARTICLE II
THE OFFER
THE OFFER
Section 2.1 The Offer
(a) Upon the terms and subject to the conditions of this Agreement (including Article
IX), as promptly as practicable (but in no event later than ten (10) Business Days following
the date of this Agreement) Merger Sub shall, and Parent shall cause Merger Sub to, commence,
within the meaning of Rule 14d-2 under the Exchange Act, the Offer; provided, that the Company
agrees that no shares of Common Stock owned by the Company will be tendered pursuant to the Offer.
The obligations of Merger Sub to, and of Parent to cause Merger Sub to, accept for payment, and pay
for, any shares of Common Stock tendered pursuant to the Offer are subject only to the satisfaction
or waiver (to the extent permitted under this Agreement) of the conditions set forth in
Exhibit A (as they may be amended in accordance with this Agreement, the “Offer
Conditions”).
(i) The initial Expiration Date shall be 12
midnight, New York City time, at the end of the 20th Business Day
following
9
commencement of the Offer (determined pursuant to Rule 14d-1(g)(3) under the
Exchange Act). Parent and Merger Sub expressly reserve the right, at any time, to,
in their sole discretion, waive, in whole or in part, any Offer Condition or modify
the terms of the Offer; provided, however, that, without the prior written consent
of the Company, neither Parent nor Merger Sub shall (A) reduce the number of shares
of Common Stock subject to the Offer, (B) reduce the Offer Price or change the form
of consideration payable in the Offer, (C) change, modify or waive the Minimum
Tender Condition, (D) impose conditions to the
Offer that are different than or in addition to the Offer Conditions, or (E)
otherwise amend the Offer in any manner materially adverse to the holders of Common
Stock.
(ii) Notwithstanding anything in this Agreement to the contrary, Parent and
Merger Sub (A) may, in their sole discretion (subject to the obligations of Parent
and Merger Sub under Section 2.1(a)(ii)(B)), without consent of the Company,
extend the Offer on one or more occasions for any period if, on any then-scheduled
Expiration Date, any of the Offer Conditions shall not be satisfied or, if in
Parent’s or Merger Sub’s sole discretion, waived (if permitted under this Agreement)
until such time as such condition or conditions are satisfied or waived and (B)
shall extend the Offer (1) for any period required by any rule, regulation,
interpretation or position of the SEC, the staff thereof or the Nasdaq Stock Market
(“Nasdaq”) applicable to the Offer, (2) for a period beginning on the
commencement of, and ending 10 Business Days after the cessation of, (a) any general
suspension in trading in, or limitation on prices for, securities on any national
securities exchange or in the over the counter market in the U.S., (b) a declaration
of a banking moratorium or any suspension of payments in respect of a banking
moratorium or any suspension of payments in respect of banks in the U.S. (whether or
not mandatory), or (c) any limitation (whether or not mandatory) imposed by any
Governmental Entity on the extension of credit by banks or other lending
institutions in the U.S., and (3) until any waiting period (and any extension
thereof) applicable to the consummation of the Offer under the HSR Act and any
applicable competition, antitrust or investment Laws of jurisdictions other than the
U.S. shall have expired or been terminated; provided, however, that in no event
shall Parent or Merger Sub be required to extend the Offer (1) beyond the
Termination Date or (2) at any time that Parent or Merger Sub are permitted to
terminate this Agreement pursuant to Article IX.
(iii) On the terms and subject to the conditions of this Agreement, Merger Sub
shall, and Parent shall cause Merger Sub to, accept and pay for (subject to any
required Tax withholding of Taxes pursuant to Section 7.13) all shares of
Common Stock validly tendered and not validly withdrawn pursuant to the Offer as
soon as practicable after the Expiration Date (as it may be extended and re-extended
in accordance with this Section 2.1(a)). The Offer Price payable in respect
of each share of Common Stock pursuant to the preceding sentence shall be paid net
to the seller in cash, without interest, on the terms and subject to the conditions
of this Agreement. Acceptance for payment of shares of Common Stock pursuant to and
subject to the conditions of the Offer upon the expiration of the Offer is referred
to in this Agreement as the “Offer Closing”, and the date on which the Offer
Closing occurs is referred to in this Agreement as the “Offer Closing Date”.
Parent and Merger Sub expressly reserve the right to, in their sole discretion,
following the Offer Closing, extend the Offer for a “subsequent offering period” in
accordance with Rule 14d-11 under the Exchange Act; provided, however, such period
(including any extensions thereof) shall not exceed
10
twenty (20) Business Days. The Offer Documents (as defined below) may, in
Parent’s and Merger Sub’s sole discretion, provide for such a reservation of right.
(iv) Nothing contained in this Section 2.1(a) shall affect any
termination rights in Article IX. Unless this Agreement is terminated
pursuant to Section 9.1, neither Parent nor Merger Sub shall terminate or
withdraw the Offer prior to any scheduled Expiration Date without the prior written
consent of the Company in its sole discretion. In the event this Agreement is
terminated pursuant to Section 9.1 before Merger Sub has accepted for
payment the shares of Common Stock tendered in the Offer, Merger Sub shall promptly
(and in any event within one (1) Business Day) following such termination
irrevocably and unconditionally terminate the Offer and shall not acquire any shares
of Common Stock pursuant thereto. If the Offer is terminated in accordance with
this Agreement prior to the purchase of shares of Common Stock in the Offer, Merger
Sub shall promptly return, or cause any depositary acting on behalf of Merger Sub to
promptly return, all tendered shares to the tendering stockholders.
(b) On the date of commencement of the Offer, Parent and Merger Sub shall file with the SEC a
tender offer statement (“Tender Offer Statement”) on Schedule TO with respect to the Offer
(together with all amendments and supplements thereto and including exhibits thereto, the
“Schedule TO”), which shall contain an offer to purchase and a related letter of
transmittal and summary advertisement and other appropriate ancillary offer documents (such
Schedule TO and the documents included therein pursuant to which the Offer will be made, together
with any supplements or amendments thereto, the “Offer Documents”), and cause the Offer
Documents to be disseminated to the stockholders of the Company as and to the extent required by
U.S. federal securities laws. The Company shall promptly furnish or otherwise make available to
Parent or Parent’s legal counsel in writing upon request all information concerning the Company
that may be reasonably requested by Parent in connection with any action contemplated by this
Section 2.1(b). Parent shall cause the Schedule TO and other Offer Documents to comply in
all material respects with the provisions of applicable Law. Parent and Merger Sub hereby further
agree that the Offer Documents, when filed with the SEC and on the date first published, sent or
given to the stockholders of the Company, shall not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading in any
material respect; provided, however, that no such obligation is undertaken by Parent or Merger Sub
with respect to information supplied by the Company or any of the Company’s officers, directors,
Representatives, agents or employees in writing specifically for inclusion or incorporation by
reference in the Offer Documents. The Company hereby agrees that the information provided by or on
behalf of the Company in writing specifically for inclusion or incorporation by reference in the
Offer Documents shall not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading in any material respect.
Each of Parent, Merger Sub and the Company shall promptly correct any information supplied by it
for inclusion or incorporation by reference in the Offer Documents if and to the extent that such
information shall have become false or misleading in any material respect, and each of Parent and
Merger Sub shall take all steps necessary to amend or supplement the Offer Documents and to cause
the Offer Documents as so amended or supplemented to be filed with the SEC and disseminated to the
stockholders of the Company, in each case as soon as reasonably practicable and as and to the
extent required by applicable U.S. federal securities laws. Parent and Merger Sub shall promptly
notify the Company upon the receipt of any comments from the SEC, or any request from the SEC for
amendments or supplements, to the Offer Documents, and shall promptly provide the Company with
copies of all correspondence and summaries of all material oral communications between them and
their officers, employees, counsel, investment bankers, accountants and other authorized
representatives (“Representatives”), on the one hand, and the SEC, on the other
11
hand. Prior to the filing of the Offer Documents (including any amendment or supplement
thereto) with the SEC or dissemination thereof to the stockholders of the Company, or responding to
any comments of the SEC with respect to the Offer Documents, Parent and Merger Sub shall provide
the Company and its counsel a reasonable opportunity to review and comment on such Offer Documents
or response, and Parent and Merger Sub shall give reasonable consideration to any such comments. In
the event that Parent or Merger Sub receives any comments from the SEC or its staff with respect to
the Offer Documents, each shall use its reasonable best efforts to (i) respond promptly to such
comments and (ii) take all other actions necessary to resolve the issues raised therein.
(c) Parent shall provide or cause to be provided to Merger Sub on a timely basis the
consideration necessary to pay for any shares of Common Stock that Merger Sub becomes obligated to
accept for payment and pay for pursuant to the Offer, and shall cause Merger Sub to fulfill all of
Merger Sub’s obligations under this Agreement.
Section 2.2 Top-Up Option.
(a) The Company grants to Parent and Merger Sub an irrevocable option (the “Top-Up
Option”), exercisable only upon the terms and conditions set forth in this Section 2.2,
to purchase from the Company, at a price per share equal to the Offer Price, the number of
newly-issued shares of Common Stock (the “Top-Up Option Shares”) equal to the lowest number
of shares of Common Stock that, when added to the number of shares of Common Stock owned by Parent
and Merger Sub at the time of exercise of the Top-Up Option, constitutes one share more than ninety
percent (90%) of the number of shares of Common Stock issued and outstanding immediately after the
issuance of all shares of Common Stock subject to the Top-Up Option; provided, however, that the
Top-Up Option may not be exercised to the extent that the number of Top-Up Option Shares exceeds
that number of shares of Common Stock authorized and unissued (treating shares owned by the Company
as treasury stock as unissued) and not reserved for issuance at the time of exercise of the Top-Up
Option with respect to any RSUs then outstanding or any In-the-Money Options. The obligation of
the Company to issue and deliver the Top-Up Option Shares upon the exercise of the Top-Up Option is
subject to the condition that no applicable Law shall be in effect that has the effect of enjoining
or otherwise prohibiting the exercise of the Top-Up Option or the issuance and delivery of the
Top-Up Option Shares.
(b) The Top-Up Option may be exercised by Parent or Merger Sub only once at any time following
the Offer Closing and prior to the earlier to occur of the Effective Time and the termination of
this Agreement pursuant to Section 9.1 hereof; provided, however, that the Top-Up Option
shall not be exercisable unless, immediately after such exercise and the issuance of shares of
Common Stock pursuant thereto, the Short-Form Threshold shall be reached. The aggregate purchase
price payable for the shares of Common Stock being purchased by Parent or Merger Sub pursuant to
the Top-Up Option shall be determined by multiplying the number of such shares by the Offer Price.
Such purchase price may be paid by Parent or Merger Sub, at their election, either (i) entirely in
cash (by wire transfer of same-day funds) or (ii) by (x) paying in cash (by wire transfer of
same-day funds) an amount equal to not less than the aggregate par value of the Top-Up Option
Shares and (y) Parent, executing and delivering to the Company a promissory note having a principal
amount equal to the balance of such purchase price, less the amount paid in cash pursuant to the
preceding clause (x), or any combination of the foregoing. Any such promissory note shall include
the following (and no other) material terms: (i) the principal amount and accrued interest under
the promissory note shall be payable upon the demand of the Company, (ii) the unpaid principal
amount of the promissory note will accrue simple interest at the per annum rate of three percent
(3.0%), (iii) the promissory note may be prepaid in whole or in part at any time and from time to
time, without premium or penalty or prior notice (iv) the promissory note shall be full recourse to
Parent and Merger Sub and (v) the unpaid principal amount and accrued interest under the promissory
note shall immediately become due and payable in the event that (A) Parent or Merger Sub
12
fails to make any payment of interest on the promissory note as provided therein and such
failure continues for a period of thirty (30) days or (B) Parent or Merger Sub files or has filed
against it any petition under any bankruptcy or insolvency law or makes a general assignment for
the benefit of creditors.
(c) In the event Parent or Merger Sub exercises the Top-Up Option, Parent or Merger Sub shall
deliver to the Company a notice setting forth (i) the number of shares of Common Stock that Merger
Sub intends to purchase pursuant to the Top-Up Option, (ii) the manner in which Parent or Merger
Sub intends to pay the applicable exercise price and (iii) the place and time at which the closing
of the purchase of such shares of Common Stock by Merger Sub is to take place. At the closing of
the purchase of such shares of Common Stock, Parent or Merger Sub shall cause to be delivered to
the Company the consideration required to be delivered in exchange for such shares, and the Company
shall cause to be issued to Merger Sub a certificate representing such shares (or, if the Company
does not then issue shares of Common Stock in certificated form, the applicable number of shares of
Common Stock in non-certificated book-entry form).
(d) In determining the fair value of any Dissenting Shares pursuant to Section 262 of the DGCL
as contemplated by Section 4.3 herein, none of Parent, Merger Sub, the Company or the Surviving
Corporation shall take into account the Top-Up Option, the Top-Up Option Shares or any promissory
note issued to pay any portion of the purchase price for such Top-Up Option Shares.
Section 2.3 Company Actions.
(a) The Company hereby approves and consents to the Transactions and represents that the
Company Board, at a meeting duly called and held, has unanimously:
(i) determined that the Transactions are advisable, fair to and in the best
interests of the stockholders of the Company;
(ii) adopted and approved this Agreement and the Transactions and declared it
advisable that the Company enter into this Agreement and consummate the
Transactions;
(iii) resolved to recommend that the Company’s stockholders accept the Offer
and approve the Merger; and
(iv) approved taking all actions so that the restrictions contained in the
Company’s certificate of incorporation, the restrictions on “business combinations”
set forth in the Delaware Takeover Statute and the restrictions on “significant
business transactions” set forth in the Washington Takeover Statute will not apply
to the execution, delivery or performance of this Agreement or to the consummation
of the Transactions, including the Merger.
(b) On the date the Offer Documents are filed with the SEC, the Company shall file with the
SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer (such
Schedule 14D-9, together with any supplements or amendments thereto, the “Schedule 14D-9”)
containing, subject to Section 7.3(c), the recommendation described in Section
2.3(a)(iii) and shall disseminate the Schedule 14D-9 to the stockholders of the Company as and
to the extent required by Rule 14d-9 under the Exchange Act. Each of Parent and Merger Sub shall
promptly furnish to the Company or the Company’s legal counsel in writing upon request all
information concerning Parent and Merger Sub
13
that may be required by applicable securities Laws or reasonably requested by the Company for
inclusion in the Schedule 14D-9. The Company shall cause the Schedule 14D-9 to comply in all
material respects with the provisions of applicable Law. The Company shall also include in the
Schedule 14D-9, and will obtain all necessary consents of the Company’s financial advisor, Xxxxx
Xxxxxxx & Co., to permit the Company to include in the Schedule 14D-9, in its entirety, the
Fairness Opinion, together with a summary thereof in accordance with Item 1015(b) of Regulation M-A
under the Exchange Act (regardless of whether Item 1015(b) is applicable). The Company hereby
consents to the inclusion in the Offer Documents of a description of
the Company Recommendation.
The Company hereby further agrees that the Schedule 14D-9, when filed
with the SEC and on the date first published, sent or given to the stockholders of the Company,
shall not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading in any material respect; provided,
however, that no such obligation is undertaken by the Company with respect to information supplied
by Parent or Merger Sub or any of their officers, directors, representatives, agents or employees
in writing specifically for inclusion or incorporation by reference in the Schedule 14D-9. Parent
and Merger Sub hereby agree that the information provided by or on behalf of them in writing
specifically for inclusion or incorporation by reference in the Schedule 14D-9 shall not contain
any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading in any material respect. Each of the Company, Parent, and
Merger Sub shall promptly correct any information supplied by it for inclusion or incorporation by
reference in the Schedule 14D-9 if and to the extent that such information shall have become false
or misleading in any material respect, and the Company shall take all steps necessary to amend or
supplement the Schedule 14D-9 and to cause the Schedule 14D-9 as so amended or supplemented to be
filed with the SEC and disseminated to the stockholders of the Company, in each case as soon as
reasonably practicable and as and to the extent required by applicable U.S. federal securities
laws. The Company shall promptly notify Parent upon the receipt of any comments from the SEC, or
any request from the SEC for amendments or supplements, to the Schedule 14D-9, and shall promptly
provide Parent with copies of all correspondence and summaries of all material oral communications
between the Company and its Representatives, on the one hand, and the SEC, on the other hand.
Prior to the filing of the Schedule 14D-9 (including any amendment or supplement thereto) that does
not contain or relate to an Acquisition Proposal or a Change of Recommendation with the SEC or
mailing thereof to the stockholders of the Company, or responding to any comments of the SEC with
respect to the Schedule 14D-9, the Company shall provide Parent, Merger Sub and their counsel a
reasonable opportunity to review and comment on such Schedule 14D-9 or response, and the Company
shall give reasonable and good faith consideration to any such comments. The Company hereby
consents to the inclusion in the Offer Documents of the recommendation of the Company Board
contained in the Schedule 14D-9. In the event that the Company receives any comments from the SEC
or its staff with respect to the Schedule 14D-9, it shall use its reasonable best efforts to (i)
respond promptly to such comments and (ii) take all other actions necessary to resolve the issues
raised therein.
(c) In connection with the Offer and the Merger, the Company shall instruct its transfer agent
to furnish Parent and Merger Sub promptly with mailing labels containing the names and addresses of
the record holders of Common Stock as of the latest practicable date and of those persons becoming
record holders subsequent to such date, together with copies of all lists of stockholders, security
position listings and computer files and all other information in the Company’s possession or
control regarding the beneficial owners of Common Stock, in each case as of the latest date
practicable, and shall furnish to Parent and Merger Sub such information and assistance (including
periodically updated lists of stockholders, security position listings and computer files) as
Parent may reasonably request in communicating the Offer to holders of Common Stock. Except for
such steps as are necessary
14
to disseminate the Offer Documents and any other documents necessary to consummate the Offer
or the Merger, Parent, Merger Sub and their respective affiliates, associates and Representatives
shall use the information contained in any such labels, listings and files only in connection with
the Offer and the Merger, shall treat such information and materials in accordance with the terms
and conditions of the Non-Disclosure Agreement, and, if this Agreement shall be terminated, will
deliver to the Company all copies of such information then in their possession or under their
control promptly upon the request of the Company.
Section 2.4 Directors.
(a) Effective upon the Offer Closing and from time to time thereafter, Parent shall be
entitled to designate the number of directors, rounded up to the next whole number, on the Company
Board that equals the product of (i) the total number of directors on the Company Board (giving
effect to the election of any additional directors pursuant to this Section 2.4) and (ii)
the percentage that the number of shares of Common Stock beneficially owned by Parent and/or Merger
Sub (including shares accepted for payment pursuant to the Offer) bears to the total number of
shares outstanding, and the Company shall, promptly following Parent’s written request, cause
Parent’s designees to be elected or appointed to the Company Board, including by increasing the
number of directors and seeking and accepting resignations of incumbent directors (with such method
to be at the election of Parent, including the selection of the individuals designated for
resignation). At each such time, the Company shall also cause individuals designated by Parent to
constitute the proportional number of members, rounded up to the next whole number, on each
committee of the Company Board in proportion to the number of directors designated by Parent to the
Company Board, to the extent permitted by applicable Law and the Nasdaq Marketplace Rules.
(b) The Company’s obligations to appoint Parent’s designees to the Company Board shall be
subject to Section 14(f) of the Exchange Act and Rule 14f-1 promulgated thereunder. The Company
shall promptly take all actions necessary to effect the appointment of Parent’s designees,
including mailing to its stockholders such information with respect to the Company and its officers
and directors as Section 14(f) and Rule 14f-1 require in order to fulfill its obligations under
this Section 2.4(b), which, unless Parent otherwise elects, shall be mailed together with
the Schedule 14D-9. Parent shall supply to the Company in writing and be solely responsible for
any information with respect to itself and its nominees, officers, directors and Affiliates
required by Section 14(f) and Rule 14f-1 and the Company’s obligations under Section 2.4(a)
hereof shall be subject to the receipt of such information.
(c) Following the election or appointment of Parent’s designees to the Company Board pursuant
to Section 2.4(a) and until the Effective Time, the Company Board shall at all times
include, and the Company, Parent and Merger Sub shall use their reasonable best efforts to cause
the Company Board to at all times include, at least three (3) Continuing Directors, and each
committee of the Company Board shall at all times include, and the Company, Parent and Merger Sub
shall use their reasonable best efforts to cause each committee of the Company Board to at all
times include, at least one (1) Continuing Director. A “Continuing Director” shall mean a
person who is a member of the Company Board as of the date of this Agreement or a person selected
by the Continuing Directors then in office, each of whom shall be an independent director for
purposes of the Nasdaq Marketplace Rules and shall be eligible to serve on the Company’s audit
committee under the Exchange Act and the Nasdaq Marketplace Rules and, at least one of whom shall
be an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-K and the
instructions thereto; provided, however that if the number of Continuing Directors is reduced to
less than three (3) prior to the Effective Time, any remaining Continuing Directors (or Continuing
Director, if there shall be only one (1) remaining) shall be entitled to designate a person who is
not an officer, director, stockholder or designee of Parent or any of its Affiliates to fill such
vacancy, and such person shall be deemed to be a Continuing Director for all purposes of this
15
Agreement, or, if no Continuing Directors then remain, the other directors shall designate
three (3) persons who are not officers, directors, stockholders or designees of Parent or any of
its Affiliates to fill such vacancies, and such persons shall be deemed to be Continuing Directors
for all purposes of this Agreement.
(d) Notwithstanding anything to the contrary set forth in this Agreement, in the event that
Parent’s designees are elected or appointed to the Company Board prior to the Effective Time
pursuant to Section 2.3(a) and between the date hereof and the Effective Time, the approval
of a majority of such Continuing Directors (or the sole Continuing Director if there shall only be
one (1) Continuing Director) shall be required to (i) terminate this Agreement or (ii) amend or
modify this Agreement, waive or exercise any rights of the Company under this Agreement, or extend
the time for performance of any of the obligations of Parent or Merger Sub under this Agreement or
amend the Company’s certificate of incorporation or bylaws, in each case in a manner adverse to the
stockholders of the Company.
ARTICLE III
THE MERGER
THE MERGER
Section 3.1 The Merger. Subject to the terms and conditions of this Agreement and in
accordance with the DGCL, at the Effective Time, the Company and Merger Sub shall consummate a
merger (the “Merger”) pursuant to which (i) Merger Sub shall merge with and into the
Company and the separate corporate existence of Merger Sub shall thereupon cease, (ii) the Company
shall be the surviving corporation (the “Surviving Corporation”) in the Merger and (iii)
the corporate existence of the Company shall continue unaffected by the Merger. The Merger shall,
from and after the Effective Time, have the effects set forth in the applicable provisions of the
DGCL and other applicable Law.
Section 3.2 Effective Time. Parent, Merger Sub and the Company shall cause a
certificate of merger in substantially the form attached hereto as Exhibit B (the
“Certificate of Merger”) to be delivered on the Closing Date (or on such other date as
Parent and the Company may agree in writing) to the Secretary of State of the State of Delaware for
filing as provided in the DGCL, and shall make all other deliveries, filings or recordings required
by the DGCL in connection with the Merger. The Merger shall become effective on the date on which
the Certificate of Merger is filed by the Secretary of State of the State of Delaware, or on such
other later date as is agreed upon by the parties and specified in the Certificate of Merger, and
at the time specified in the Certificate of Merger or, if not specified therein, by the DGCL, and
such time on such date of effectiveness is hereinafter referred to as the “Effective Time.”
Section 3.3 Closing. The closing of the Merger (the “Closing”) will take
place at 10:00 A.M., Pacific Time, on a date to be specified by the parties, which shall be no
later than two (2) Business Days after satisfaction or waiver of all of the conditions set forth
in Article VIII hereof (other than conditions that by their terms are to be satisfied at
the Closing, but subject to the satisfaction or waiver of such conditions at the Closing), at the
offices of Xxxxxxx Coie LLP, 0000 Xxxxx Xxxxxx, 00xx Xxxxx, Xxxxxxx, Xxxxxxxxxx, unless another
time, date or place is agreed to in writing by the parties hereto (such date on which the Closing
is to take place being the “Closing Date”).
Section 3.4 Certificate of Incorporation and Bylaws of the Surviving Corporation. The
certificate of incorporation of the Company, as in effect immediately prior to the Effective Time,
shall at the Effective Time be amended and restated in full to read as set forth in
Exhibit C and as so amended and restated shall be the certificate of incorporation of the
Surviving Corporation, until thereafter amended as provided by Law and such certificate of
incorporation. The
16
bylaws of the Surviving Corporation shall, as of the Effective Time, be amended and restated
in their entirety to be the same as the bylaws of Merger Sub, as in effect immediately prior to the
Effective Time, except as to the name of the Surviving Corporation, which shall be Cardiac Science
Corporation, until thereafter amended as provided by Law, the certificate of incorporation of the
Surviving Corporation and such bylaws.
Section 3.5 Directors and Officers of the Surviving Corporation. The directors of
Merger Sub, as of immediately prior to the Effective Time shall, from and after the Effective Time,
be the directors of the Surviving Corporation until their successors shall have been duly elected
or appointed or qualified or until their earlier death, resignation or removal in accordance with
the Surviving Corporation’s certificate of incorporation and bylaws. The officers of the Company
at the Effective Time shall, from and after the Effective Time, be the initial officers of the
Surviving Corporation until their successors shall have been duly elected or appointed or qualified
or until their earlier death, resignation or removal in accordance with the Surviving Corporation’s
certificate of incorporation and bylaws.
ARTICLE IV
CONVERSION OF SHARES
CONVERSION OF SHARES
Section 4.1 Conversion of Shares.
(a) At the Effective Time, each share of Common Stock, issued and outstanding immediately
prior to the Effective Time (other than shares of Common Stock to be cancelled pursuant to
Section 4.1(c) and Dissenting Shares) shall, by virtue of the Merger and without any action
on the part of the holder thereof, be converted into the right to receive an amount in cash equal
to the Offer Price paid in the Offer (the “Merger Consideration”) without any interest
thereon.
(b) Each share of common stock, $0.01 par value per share, of Merger Sub issued and
outstanding immediately prior to the Effective Time shall, at the Effective Time, by virtue of the
Merger and without any action on the part of Parent, be converted into one fully paid and
nonassessable share of the common stock, $0.01 par value per share, of the Surviving Corporation.
(c) Any shares of Common Stock held in the treasury of the Company or owned by Parent, Merger
Sub or any other direct or indirect wholly owned Subsidiary of Parent shall, at the Effective Time,
be cancelled and shall cease to exist, and no consideration shall be delivered in exchange
therefor.
(d) At the Effective Time, each share of Common Stock converted into the right to receive the
Merger Consideration pursuant to Section 4.1(a) shall be automatically cancelled and shall
cease to exist, and the holders immediately prior to the Effective Time of shares of outstanding
Common Stock not represented by certificates (“Book-Entry Shares”) and the holders of
certificates that, immediately prior to the Effective Time, represented shares of outstanding
Common Stock (the “Certificates”) shall cease to have any rights with respect to such
shares of Common Stock other than the right to receive, upon surrender of such Book-Entry Shares or
Certificates in accordance with Section 4.2, the Merger Consideration, without any interest
thereon, for each such share of Common Stock held by them.
(e) If at any time between the date of this Agreement and the Effective Time any change in the
number of outstanding shares of Common Stock shall occur as a result of a reclassification,
recapitalization, stock split (including a reverse stock split), or combination, exchange or
readjustment of shares, or any stock dividend or stock distribution with a record date during such
period,
17
the amount of the Merger Consideration as provided in Section 4.1(a) shall be
equitably adjusted to reflect such change.
Section 4.2 Exchange of Certificates and Book-Entry Shares.
(a) At or prior to the Closing, Parent shall deliver, in trust, to a paying agent reasonably
acceptable to the Company (the “Paying Agent”), for the benefit of the holders of shares of
Common Stock at the Effective Time, sufficient funds for timely payment of the aggregate Merger
Consideration (such cash being hereinafter referred to as the “Consideration Fund”)
to be paid pursuant to this Section 4.2 in respect of Certificates and Book-Entry Shares,
assuming no Dissenting Shares and all amounts payable under Section 4.4. In the event the
Consideration Fund shall be insufficient to pay the aggregate Merger Consideration contemplated by
Section 4.1 and all amounts payable under Section 4.4, Parent shall promptly
deliver, or cause to be delivered, additional funds to the Paying Agent in an amount that is equal
to the deficiency required to make such payments.
(b) Promptly after the Effective Time, Parent shall cause the Paying Agent to mail to each
holder of record of Certificates or Book-Entry Shares whose shares were converted into the right to
receive Merger Consideration pursuant to Section 4.1 (i) a letter of transmittal that shall
specify that delivery of such Certificates or Book-Entry Shares shall be deemed to have occurred,
and risk of loss and title to the Certificates or Book-Entry Shares, as applicable, shall pass,
only upon proper delivery of the Certificates (or affidavits of loss in lieu thereof) or Book-Entry
Shares, as applicable, to the Paying Agent and (ii) instructions for use in effecting the surrender
of the Certificates or Book-Entry Shares in exchange for payment of the Merger Consideration and
amounts payable under Section 4.4, the form and substance of which letter of transmittal
and instructions shall be substantially as reasonably agreed to by the Company and Parent and
prepared prior to the Closing. Upon surrender of a Book-Entry Share or a Certificate for
cancellation to the Paying Agent together with such letter of transmittal, duly executed and
completed in accordance with the instructions thereto, and with such other documents as may be
required pursuant to such instructions, the holder of such Book Entry Share or Certificate shall be
entitled to receive in exchange therefor, subject to any required withholding of Taxes pursuant to
Section 7.13, the Merger Consideration pursuant to the provisions of this Article
IV, and the Book-Entry Share or Certificate so surrendered shall forthwith be cancelled. No
interest will be paid or accrued on the Merger Consideration payable to holders of Book-Entry
Shares or Certificates. If any Merger Consideration is to be paid to a Person other than a Person
in whose name the Book-Entry Share or Certificate surrendered in exchange therefor is registered,
it shall be a condition of such exchange that the Person requesting such exchange shall pay to the
Paying Agent any transfer or other Taxes required by reason of payment of the Merger Consideration
to a Person other than the registered holder of the Book-Entry Share or Certificate or shall
establish to the reasonable satisfaction of the Paying Agent that such Tax has been paid or is not
applicable.
(c) The Consideration Fund shall be invested by the Paying Agent as directed by Parent or the
Surviving Corporation; provided, however, that any such investments shall be in money market mutual
or similar funds having assets in excess of $10,000,000,000. Earnings on the Consideration Fund
shall be the sole and exclusive property of Parent and the Surviving Corporation and shall be paid
to Parent or the Surviving Corporation, as Parent directs. No investment or loss of the
Consideration Fund shall relieve Parent, the Surviving Corporation or the Paying Agent from
promptly making the payments required by this Article IV, and following any losses from any
such investment, Parent shall promptly provide additional funds to the Paying Agent for the benefit
of the holders of shares of Common Stock at the Effective Time in the amount of such losses, which
additional funds will be deemed to be part of the Consideration Fund.
18
(d) At and after the Effective Time, there shall be no transfers on the stock transfer books
of the Company of the shares of Common Stock that were outstanding immediately prior to the
Effective Time. If, after the Effective Time, Certificates or Book-Entry Shares are presented to
the Surviving Corporation or the Paying Agent for any reason, they shall be cancelled and exchanged
for the Merger Consideration pursuant to this Article IV, except as otherwise provided by
Law.
(e) Any portion of the Consideration Fund (including the proceeds of any investments thereof)
that remains unclaimed by the former stockholders of the Company one (1) year after the Effective
Time shall be delivered to Parent. Any holders of Certificates or Book-Entry Shares who have not
theretofore complied with this Article IV with respect to such Certificates or Book-Entry
Shares shall thereafter look only to Parent for payment of their claim for Merger Consideration in
respect thereof.
(f) Notwithstanding the foregoing, neither the Paying Agent nor any party hereto shall be
liable to any Person in respect of cash from the Consideration Fund delivered to a public official
pursuant to any applicable abandoned property, escheat or similar Law. If any Certificate or
Book-Entry Share shall not have been surrendered prior to the date on which any Merger
Consideration in respect thereof would otherwise escheat to or become the property of any
Governmental Entity, any such Merger Consideration in respect of such Certificate or Book-Entry
Share shall, to the extent permitted by applicable Law, become the property of Parent, and any
holder of such Certificate or Book-Entry Share who has not theretofore complied with this
Article IV with respect thereto shall thereafter look only to Parent for payment of their
claim for Merger Consideration in respect thereof.
(g) If any Certificate shall have been lost, stolen or destroyed, upon the making of an
affidavit of that fact (such affidavit shall be in a form reasonably satisfactory to Parent and the
Paying Agent) by the Person claiming such Certificate to be lost, stolen or destroyed and, if
required by Parent, the posting by such Person of a bond in such reasonable amount as Parent may
direct as indemnity against any claim that may be made against it with respect to such Certificate,
the Paying Agent shall issue in exchange for such lost, stolen or destroyed Certificate, the Merger
Consideration to which such Person is entitled in respect of such Certificate pursuant to this
Article IV.
Section 4.3 Shares of Dissenting Stockholders.
(a) Notwithstanding anything in this Agreement other than Section 4.3(b) to the
contrary, any shares of Common Stock that are issued and outstanding immediately prior to the
Effective Time and held by a stockholder who has not voted in favor of the Merger or consented
thereto in writing and who has demanded properly in writing appraisal for such shares of Common
Stock in accordance with Section 262 of the DGCL (“Dissenting Shares”) shall not be
converted into the right to receive the Merger Consideration unless and until such stockholder
shall have effectively withdrawn or lost (through failure to perfect or otherwise) such
stockholder’s right to obtain payment of the fair value of such stockholder’s Dissenting Shares
under Section 262 of the DGCL, but shall instead be entitled only to such rights with respect to
such Dissenting Shares as may be granted to such stockholder under Section 262 of the DGCL. From
and after the Effective Time, Dissenting Shares shall not be entitled to vote for any purpose or be
entitled to the payment of dividends or other distributions (except dividends or other
distributions payable to stockholders of record prior to the Effective Time). The Company shall
promptly provide any notices of dissent or demands for appraisal of any shares of Common Stock to
Parent, and Parent shall have the right to participate in and direct all negotiations and
proceedings with respect to each such dissent or demand. Except with the prior written consent of
Parent, the Company shall not make any payment with respect to, or offer to settle or settle, any
such dissent or demand, or agree to do any of the foregoing.
19
(b) If any stockholder who holds Dissenting Shares effectively withdraws or loses (through
failure to perfect or otherwise) such stockholder’s right to obtain payment of the fair value of
such stockholder’s Dissenting Shares under Section 262 of the DGCL, then, as of the later of the
Effective Time and the occurrence of such effective withdrawal or loss, such stockholder’s shares
of Common Stock shall no longer be Dissenting Shares and, if the occurrence of such effective
withdrawal or loss is later than the Effective Time, shall be treated as if they had as of the
Effective Time been converted into the right to receive the Merger Consideration, without interest,
as set forth in subsection (a) of Section 4.1.
Section 4.4 Treatment of Stock Awards; ESPP.
(a) Company Options. Each option to purchase Common Stock (excluding any purchase
rights outstanding under the ESPP) that is outstanding immediately prior to the Effective Time (an
“Option”) and that has an exercise price per share of Common Stock less than the Merger
Consideration (an “In the Money Option”) shall, without any further action on the part of
the holder of such In the Money Option, be cancelled at the Effective Time and the holder of such
Option will, in substitution for and full settlement of such Option, be entitled to receive from
Parent an amount, subject to any required withholding of Taxes pursuant to Section 7.14, in cash
equal to the product of (x) the Merger Consideration less the exercise price per share of the
Common Stock of such Option multiplied by (y) the number of shares of Common Stock subject to such
Option (such product, the “Option Consideration”). Before the Effective Time, the Company
shall take all actions (including causing the Company Board to take all actions) that are necessary
to provide for (i) the acceleration of vesting of the In the Money Options contingent on the
Closing such that all In the Money Options will be fully vested immediately prior to the Effective
Time and (ii) the termination at the Effective Time of all In the Money Options in exchange for the
applicable Option Consideration. Each Option that is not an In the Money Option will not be
assumed or substituted for and will terminate at the Effective Time without any further action by
the holder thereof in accordance with the terms of the applicable Company Equity Plan. Promptly
after the date of this Agreement, the Company shall deliver written notice to each holder of an
Option informing such holder of the effect of the Merger on the Options.
(b) Restricted Stock Units. Each restricted stock unit on the Common Stock that is
outstanding immediately prior to the Effective Time (a “RSU”) shall be cancelled at the
Effective Time and the holder of such RSU will, in full settlement of such RSU, be entitled to
receive from Parent an amount, subject to any required withholding of Taxes pursuant to Section
7.14, in cash equal to the product of (x) the Merger Consideration multiplied by (y) the maximum
number of shares of Common Stock subject to such RSU (such product, the “RSU
Consideration”). Before the Effective Time, the Company will take all actions (including
causing the Company Board to take all actions) that are necessary to give effect to the
transactions contemplated by this Section 4.5(b).
(c) Waivers. Promptly after the date of this Agreement, the Company shall use its
reasonable best efforts to obtain all necessary waivers, consents or releases, if any, in form and
substance reasonably satisfactory to Parent, from holders of Options and RSUs and take all such
other action, without incurring any liabilities in connection therewith, as Parent may deem to be
necessary or reasonably required to give effect to the transactions contemplated by
Section 4.4(a) or (b).
(d) Company ESPP. The Company’s ESPP shall continue to be operated in accordance with
its terms and past practice for the Purchase Period (as defined in the ESPP) that is in effect on
the date of this Agreement (the “Current Purchase Period”); provided that if the Offer
Closing is expected to occur prior to the end of the Current Purchase Period, the Company shall
take all actions (including causing the Company Board to take all actions) to provide for an
earlier Purchase Date (as defined in the ESPP) in accordance with Section 20.3 of the ESPP. Such
earlier Purchase Date shall be as
20
close to the Offer Closing Date as is administratively practicable, and the Company shall
notify each participant in writing, at least ten (10) days prior to the earlier Purchase Date, that
the Purchase Date for his or her option (including for purposes of determining the Purchase Price
(as defined in the ESPP) of such option) has been changed to the earlier Purchase Date and that his
or her option will be exercised automatically on the earlier Purchase Date, unless prior to such
date he or she has withdrawn from the Purchase Period as provided in Section 11 of the ESPP.
Further, the Company shall take action (including causing the Company Board to take all actions) to
(i) clarify that no new participants may commence participation in the Current Purchase Period and
(ii) suspend the commencement of any future Purchase Periods after the date of this Agreement
unless and until this Agreement is terminated and shall terminate the ESPP as of the Offer Closing
Date.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
Except (a) as is disclosed in the last annual report on Form 10-K (and any amendments thereto)
filed by the Company with the SEC and in any Company SEC Reports filed subsequent to such annual
report, in the case of both such annual report and such other Company SEC Reports, filed prior to
the date of this Agreement, other than disclosures referred to in the “Risk Factors” or
“Forward-Looking Statements” sections, as applicable, of such annual report on Form 10-K or Company
SEC Reports to the extent that such disclosures are predictive, cautionary or forward-looking or
(b) as set forth in the Company Disclosure Schedule, the Company represents and warrants to Parent
and Merger Sub as follows:
Section 5.1 Organization. Each of the Company and its Subsidiaries is a corporation
or other entity duly organized and validly existing under the laws of the jurisdiction of its
incorporation or organization and has the requisite entity power and authority to own, lease and
operate its properties and to carry on its business as it is now being conducted. Each of the
Company and its Subsidiaries is duly qualified or licensed to do business and is in good standing
in each jurisdiction in which the nature of the business conducted by it makes such qualification
or licensing necessary, except where the failure to be so duly qualified or licensed and in good
standing would not, individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect. The Company has made available to Parent a copy of the Company’s and each
Subsidiary’s certificate of incorporation and bylaws, as currently in effect, and is not in
violation of any provision of such certificate of incorporation or bylaws.
Section 5.2 Capitalization.
(a) The authorized capital stock of the Company consists of (i) 65,000,000 shares of Common
Stock, $0.001 par value per share, 23,867,815 of which are issued and outstanding as of
the close of business on the date immediately preceding
the date of this
Agreement and (ii) 10,000,000 shares of preferred stock, $0.001 par value per share, none of which
are issued and outstanding on the date of this Agreement. All of the outstanding shares of the
Company’s capital stock are duly authorized, validly issued, fully paid, nonassessable and free of
preemptive rights. As of the date hereof, other than pursuant to the Company Equity Plans and
except as set forth in Section 5.2(a) of the Company Disclosure Schedule, there are no
existing (i) options, warrants, calls, subscriptions or other rights, convertible securities,
agreements or commitments of any character obligating the Company or any of its Subsidiaries to
issue, transfer or sell any shares of capital stock or other equity interest in, the Company or any
of its Subsidiaries, (ii) contractual obligations of the Company or any of its Subsidiaries to
repurchase, redeem or otherwise acquire any capital stock of the Company or any of its Subsidiaries
or (iii) voting trusts or similar agreements, to which the Company is a party with respect to the
voting of the capital stock of the Company. Section 5.2(a) of the Company Disclosure
Schedule contains a complete and accurate list of all Options, RSUs and other purchase rights
21
under the Equity Plans outstanding as of the date of this Agreement together with the
applicable exercise price.
(b) Except as set forth in Section 5.2(b) of the Company Disclosure Schedule, all of
the outstanding shares of capital stock or equivalent equity interests of each of the Company’s
Subsidiaries are owned of record and beneficially, directly or indirectly, by the Company free and
clear of all liens, pledges, security interests or other encumbrances other than any transfer
restrictions of general applicability as may be provided under the Securities Act and the “blue
sky” Laws of the various States of the U.S. Section 5.2(b) of the Company Disclosure
Schedule lists all Subsidiaries of the Company and the jurisdiction of their incorporation or
organization.
(c) Neither the Company nor any of its Subsidiaries owns any interest or investment (whether
equity or debt) in any corporation, partnership, joint venture, trust or other entity, other than a
Subsidiary of the Company, which interest or investment is material to the Company and its
Subsidiaries, taken as a whole.
Section 5.3 Authorization; Validity of Agreement; Company Action.
(a) The Company has the requisite corporate power and authority to execute and deliver this
Agreement and, subject to obtaining the approval of the Merger by the holders of a majority of the
issued and outstanding shares of Common Stock (the “Required Company Stockholder Vote”), if
required, to consummate the Transactions. The execution, delivery and performance by the Company
of this Agreement and the consummation by the Company of the Transactions have been duly authorized
by the Company Board, and no other corporate action on the part of the Company is necessary to
authorize the execution and delivery by the Company of this Agreement and, except for the Required
Company Stockholder Vote, if required, the consummation by it of the Transactions. This Agreement
has been duly executed and delivered by the Company and is a valid and binding obligation of the
Company enforceable against the Company in accordance with its terms, except that (i) such
enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium or
other similar laws, now or hereafter in effect, affecting creditors’ rights and remedies generally
and (ii) the remedy of specific performance and injunctive and other forms of equitable relief may
be subject to equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought.
(b) The Company Board, at a meeting duly called and held, unanimously adopted resolutions (i)
determining that the Transactions are advisable, fair to and in the best interests of the
stockholders of the Company, (ii) adopting and approving this Agreement and the Transactions and
declaring it advisable that the Company enter into this Agreement and consummate the Transactions,
(iii) recommending that the Company’s stockholders accept the Offer and approve the Merger and
(iv) approving taking all actions on behalf of the Company so that the restrictions contained in
its certificate of incorporation, the restrictions on “business combinations” set forth in the
Delaware Takeover Statute and the restrictions on “significant business transactions” set forth in
the Washington Takeover Statute will not apply to the execution, delivery or performance of this
Agreement or to the consummation of the Transactions, including the Merger.
(c) Xxxxx Xxxxxxx & Co. has delivered to the Company Board Xxxxx Xxxxxxx & Co.’s opinion to
the effect that, as of the date of such Fairness Opinion and based on the assumptions,
qualifications and limitations contained therein, the
Offer Price and the Merger Consideration, taken together, are fair, from a financial
point of view, to the holders of Common Stock (other than Common
Stock held by Parent or its Affiliates) (the “Fairness Opinion”). The Company will make available
to Parent a correct and complete copy of the form of such opinion solely for informational purposes
as soon as possible after the receipt thereof by the Company.
22
Section 5.4 Consents and Approvals; No Violations. The execution and delivery of this
Agreement by the Company do not, and the performance by the Company of this Agreement and, subject
to the approval of the Company’s stockholders (to the extent required), the consummation by the
Company of the Transactions will not, except as set forth in Section 5.4 of the Company
Disclosure Schedule, (a) violate any provision of the certificate of incorporation or bylaws of
the Company, (b) result in a violation or breach of, or constitute (with or without due notice or
lapse of time or both) a default (or give rise to any right of termination, cancellation or
acceleration) under, any of the terms, conditions or provisions of any Material Contract to which
the Company or any of its Subsidiaries is a party or by which any of them or any of their
properties or assets is bound, (c) violate any Law applicable to the Company, any of its
Subsidiaries or any of their properties or assets or (d) other than in connection with or
compliance with (A) the DGCL, (B) requirements under other state corporation Laws, (C) the HSR Act,
if applicable, and any applicable competition, antitrust or investment Laws of jurisdictions other
than the U.S., (D) Nasdaq rules and listing standards and (E) the Exchange Act, including, without
limitation, the filing with the SEC of the Schedule 14D-9 and the Proxy Statement, require the
Company to make any filing or registration with or notification to, or require the Company to
obtain any authorization, consent or approval of, any court, legislative, executive or regulatory
authority or agency (a “Governmental Entity”); except, in the case of clauses (b), (c) and
(d), for such violations, breaches or defaults that, or filings, registrations, notifications,
authorizations, consents or approvals the failure of which to make or obtain, (1) would not,
individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect,
or (2) would occur or be required as a result of the business or activities in which Parent or
Merger Sub is or proposes to be engaged or as a result of any acts or omissions by, or the status
of any facts pertaining to, Parent or Merger Sub.
Section 5.5 SEC Reports; Disclosure Controls.
(a) The Company has filed all reports and other documents with the SEC required to be filed or
furnished by the Company since December 31, 2007 (such documents, together with any reports filed
during such period by the Company with the SEC on a voluntary basis on Form 8-K, the “Company
SEC Reports”). As of their respective filing dates, the Company SEC Reports (i) complied in
all material respects with, to the extent in effect at the time of filing, the applicable
requirements of the Securities Act and the Exchange Act and (ii) did not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. Each of the financial statements (including the related notes) of the
Company included in the Company SEC Reports complied at the time it was filed as to form in all
material respects with the applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto in effect at the time of such filing, was prepared in
accordance with generally accepted accounting principles in the U.S. (“GAAP”) (except, in
the case of unaudited statements, as permitted by the rules and regulations of the SEC) applied on
a consistent basis during the periods involved (except as may be indicated in the notes thereto)
and fairly presented in all material respects the consolidated financial position of the Company
and its consolidated Subsidiaries as of the respective dates thereof and the consolidated results
of their operations and cash flows for the respective periods then ended (subject, in the case of
unaudited statements, to normal year-end adjustments).
(b) The Company has established and maintains “disclosure controls and procedures” (as defined
in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) reasonably designed and
maintained to ensure that all information (both financial and non-financial) required to be
disclosed by the Company in the reports that it files or submits to the SEC under the Exchange Act
is recorded, processed, summarized and reported within the time periods specified in the rules and
forms of the SEC and that such information is accumulated and communicated to the Company’s
management as appropriate to allow timely decisions regarding required disclosure and to
23
make the certifications of the chief executive officer and chief financial officer of the
Company required under the Exchange Act with respect to such reports. The Company has established
and maintains “internal control over financial reporting” (as defined in Rules 13a-15(f) and
15d-15(f) promulgated under the Exchange Act) sufficient to provide reasonable assurances that (i)
transactions are executed only in accordance with management’s authorization, (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to
maintain accountability for assets, (iii) access to assets is permitted only in accordance with
management’s authorization, and (iv) the recorded accountability for assets is compared with the
existing assets at reasonable intervals to prevent or timely detect the unauthorized acquisition,
use or disposition of the assets of the Company and its Subsidiaries that could have a material
effect on the Company’s financial statements. Since the date of the filing of the Company’s most
recent annual report on Form 10-K, prior to the date of this Agreement, the Company’s outside
auditors and the audit committee of the Company Board have not been advised of (x) any significant
deficiencies or material weaknesses in the design or operation of internal control over financial
reporting which adversely affect the Company’s ability to record, process, summarize and report
financial information, and (y) any fraud, whether or not material, that involves management or
other employees who have a significant role in the Company’s internal control over financial
reporting. Any material change in internal control over financial reporting and any significant
deficiency or material weakness in the design or operation of internal control over financial
reporting required to be disclosed in any Company SEC Report has been so disclosed and each
significant deficiency and material weakness previously so disclosed has been remediated. The
principal executive officer and principal financial officer of the Company have made all
certifications required by the Xxxxxxxx-Xxxxx Act, the Exchange Act and any related rules and
regulations promulgated by the SEC with respect to the Company SEC Reports, and the statements
contained in such certifications are complete and correct, and the Company reasonably believes that
they will be able to make such certifications, without qualification, when next due.
Section 5.6 No Undisclosed Liabilities. Except for (a) liabilities and obligations
incurred in the ordinary course of business and consistent with past practice since December 31,
2009, (b) liabilities and obligations disclosed on the consolidated balance sheet of the Company
included in the most recent annual report on Form 10-K, (c) liabilities and obligations incurred in
connection with the Merger or otherwise as contemplated by this Agreement, and (d) liabilities and
obligations that would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, since December 31, 2009, neither the Company nor any of its
Subsidiaries has incurred any liabilities or obligations that would be required to be reflected or
reserved against in a consolidated balance sheet of the Company and its consolidated Subsidiaries
prepared in accordance with GAAP as applied in preparing the consolidated balance sheet of the
Company and its consolidated Subsidiaries included in the Company SEC Reports.
Section 5.7 Material Contracts.
(a) As of the date hereof and other than as reflected in a Company SEC Report, the Company is
not a party to or bound by any Contract, except as set forth in Section 5.7(a) of the Company
Disclosure Schedule, (i) that would be required to be filed by the Company as a material
contract pursuant to Item 601(b)(10) of Regulation S-K of the SEC, (ii) that would, after giving
effect to the Merger, limit or restrict the Surviving Corporation or any successor thereto from
engaging in any line of business or in any geographic area, (iii) with any supplier, customer,
distributor, OEM, reseller, licensee or licensor (other than standard licenses purchased by the
Company for off-the-shelf software) that is reasonably likely to involve annual consideration to
any party thereto in excess of $250,000, (iv) with respect to joint venture or similar arrangements
providing for sharing of profits or revenue with any other person, (v) relating to indebtedness for
borrowed money, a conditional sale or, guarantee or (vi)
24
relating to a capitalized lease obligation in excess of $250,000. Each such contract
described in the foregoing clauses (i), (ii), (iii), (iv), (v) and (vi) is referred to herein as a
“Material Contract.”
(b) Each Material Contract is a valid and binding obligation of the Company enforceable
against the Company in accordance with its terms and, to the Company’s knowledge, each other party
thereto, and is in full force and effect, and the Company has performed all obligations required to
be performed by it to the date hereof under each Material Contract and, to the Company’s knowledge,
each other party to each Material Contract has performed all obligations required to be performed
by it under such Material Contract, except in each case as would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect. The Company has not
received notice, nor does it have knowledge, of any violation of or default of any obligation under
(or any condition which with the passage of time or the giving of notice would cause such a
violation of or default under) any Material Contract to which it is a party or by which it or any
of its properties or assets is bound, except in each case for such violations, defaults or
conditions that would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
Section 5.8 Employee Benefit Plans; ERISA.
(a) Section 5.8(a) of the Company Disclosure Schedule sets forth a list of all
material employee benefit plans, including plans described in section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (“ERISA”), maintained for the benefit of
any current or former employee, officer or director of the Company or any of its Subsidiaries by
the Company or by any trade or business, whether or not incorporated, which together with the
Company is treated as a single employer under section 414(b) or (c) of the Code (each such plan, a
“Benefit Plan”) and all material employment and severance agreements currently in effect
between the Company or any of its Subsidiaries and any of their respective employees (each such
agreement, a “Benefit Agreement”).
(b) With respect to each Benefit Plan and Benefit Agreement: (i) if intended to be qualified
under section 401(a) of the Code, such Benefit Plan (A) is the subject of an unrevoked favorable
determination letter from the IRS, (B) has remaining a period of time under the Code or applicable
Treasury regulations or IRS pronouncements in which to request, and make any amendments necessary
to obtain, such a letter from the IRS, or (C) is a prototype or volume submitter plan entitled,
under applicable IRS guidance, to rely on the favorable opinion or advisory letter issued by the
IRS to the sponsor of such prototype or volume submitter plan, and, to the knowledge of the
Company, nothing has occurred since the date of the most recent such determination, opinion or
advisory letter that would adversely affect such qualification, (ii) to the knowledge of the
Company, such Benefit Plan or Benefit Agreement has been administered in accordance with its terms
and applicable Law, and (iii) no disputes are pending, or, to the knowledge of the Company,
threatened that, if decided adversely to the Company, would give rise to liability on the part of
the Company.
(c) None of the Company or its Subsidiaries sponsors, maintains or contributes to, or during
the last six (6) years has sponsored, maintained or contributed to (or been obligated to sponsor,
maintain or contribute to), (i) a “multiemployer plan,” as defined in section 3(37) of ERISA, (ii)
a multiple employer plan within the meaning of section 4063 or 4064 of ERISA, or (iii) an employee
benefit plan that is subject to section 302 of ERISA, Title IV of ERISA or section 412 of the Code.
(d) All contributions required to be made to any Benefit Plan by applicable law or regulation
or by any plan document or other contractual undertaking, and all premiums due or payable with
respect to insurance policies funding any Benefit Plan, for any period through the date hereof have
been timely made or paid in full or, to the extent not required to be made or paid on or before
25
the date hereof, have been reflected on the Company’s financial statements to the extent
required by GAAP.
(e) None of Company or its Subsidiaries nor, to the knowledge of the Company, any other
Person, including any fiduciary, has engaged in any “prohibited transaction” (as defined in
Section 4975 of the Code or Section 406 of ERISA), which would reasonably be expected to subject
any of the Benefit Plans or their related trusts, the Company, any Company Subsidiary or, to the
knowledge of the Company, any Person that the Company or any Company Subsidiary has an obligation
to indemnify, to any material Tax or penalty imposed under Section 4975 of the Code or Section 502
of ERISA.
(f) With respect to each Benefit Plan that is subject to Title IV or Section 302 of ERISA or
Section 412 or 4971 of the Code, (i) there does not exist any accumulated funding deficiency within
the meaning of Section 412 of the Code or Section 302 of ERISA, whether or not waived, and,
(ii) except as would not have, individually or in the aggregate, a Company Material Adverse Effect:
(A) the fair market value of the assets of such Benefit Plan equals or exceeds the actuarial
present value of all accrued benefits under such Benefit Plan (whether or not vested) based on the
assumptions used in the latest annual actuarial report for such plan; (B) no reportable event
within the meaning of Section 4043(c) of ERISA for which the 30-day notice requirement has not been
waived has occurred; (C) all premiums to the Pension Benefit Guaranty Corporation (the
“PBGC”) have been timely paid in full; (D) no liability (other than for premiums to the
PBGC) under Title IV of ERISA has been or would reasonably be expected to be incurred by the
Company or any Company Subsidiary; and (E) to the knowledge of the Company, the PBGC has not
instituted proceedings to terminate any such Benefit Plan and, to the Company’s knowledge, no
condition exists which would reasonably be expected to constitute grounds under Section 4042 of
ERISA for the termination of, or the appointment of a trustee to administer, any such Benefit Plan.
(g) The Company and the Company Subsidiaries have no liability for life, health, medical or
other welfare benefits to former employees or beneficiaries or dependents thereof, except for
health continuation coverage as required by Section 4980B of the Code or Part 6 of Title I of ERISA
and at no expense to the Company and the Company Subsidiaries.
(h) Except as set forth in Section 5.8(h) of the Company Disclosure Schedule, neither
the execution nor the delivery of this Agreement nor the consummation of the transactions
contemplated by this Agreement will, either alone or in conjunction with any other event (whether
contingent or otherwise), (i) result in any payment or benefit becoming due or payable, or required
to be provided, to any director, employee or independent contractor of the Company or any Company
Subsidiary, (ii) increase the amount or value of any benefit or compensation otherwise payable or
required to be provided to any such director, employee or independent contractor, (iii) result in
the acceleration of the time of payment, vesting or funding of any such benefit or compensation or
(iv) result in any amount failing to be deductible by reason of Section 280G of the Code.
(i) Each Company Benefit Plan and each Company employment agreement that is a “nonqualified
deferred compensation plan” within the meaning of Section 409A of the Code and any award
thereunder, in each case that is subject to Section 409A of the Code, has been established and
maintained in all material respects in accordance with the requirements of Section 409A of the Code
and the Treasury Regulations thereunder.
Section 5.9 Litigation. Except as set forth in Section 5.9 of the Company
Disclosure Schedule, as of the date hereof, there is no action, claim, suit or proceeding
pending or, to the
26
knowledge of the Company, threatened, that would reasonably be expected to materially affect
the Company, any of its Subsidiaries, or their respective assets or businesses.
Section 5.10 Compliance with Law. Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect, neither the Company
nor any of its Subsidiaries is in violation of, or in default under, any Law, in each case,
applicable to the Company or any of its Subsidiaries or any of their respective assets and
properties. Notwithstanding the foregoing, this Section 5.10 shall not apply to employee
benefit plans, Taxes, Environmental Laws, labor matters, and FDA regulatory compliance which are
the subject exclusively of the representations and warranties in Section 5.8, Section
5.12, Section 5.14, Section 5.15 and Section 5.16, respectively.
Section 5.11 Intellectual Property.
(a) Section 5.11 of the Company Disclosure Schedule sets forth all (i) issued patents
and pending patent applications, (ii) trademark registrations and applications for registration
thereof and (iii) copyright registrations, in each case that are owned by or on behalf of the
Company or any of its Subsidiaries. With respect to each item of Intellectual Property required to
be identified in this Section 5.11, except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect: (x) except as set forth in
Section 5.11(a) of the Company Disclosure Schedule, the Company or one of its Subsidiaries
own all right, title, and interest in and to such item, free and clear of any lien other than
Permitted Liens; (y) such item is not subject to any outstanding injunction, judgment, or order of
any Governmental Entity of which the Company has received written notice; and (z) no lawsuit of
which the Company has received written notice is pending or, to the knowledge of the Company, is
threatened that challenges the validity or enforceability of such item. Section 5.11(a) of the
Company Disclosure Schedule also lists any licenses granted by the Company or its Subsidiaries
with respect to Intellectual Property, including the name of the licensee(s).
(b) Section 5.11(b) of the Company Disclosure Schedule sets forth a list of all
material agreements under which the Company or any of its Subsidiaries licenses from a third party
material Intellectual Property that is used by the Company or such Subsidiary in the conduct of its
business, as presently conducted, except for off-the-shelf software programs and other readily
available commercial software that the Company and any of its Subsidiaries use in the ordinary
course of business in accordance with the terms of any applicable licenses related thereto (such
agreements being referred to as “License-In Agreements”). Each License-In Agreement is
valid, binding, and in full force and effect against the Company or its Subsidiaries and to the
knowledge of the Company against any other party thereto. Neither the Company nor any of its
Subsidiaries is in material default of any such License-In Agreement, and no event has occurred
that constitutes a material default thereunder, except for any of the foregoing that have not had,
and are not reasonably expected to have, a Company Material Adverse Effect. To the knowledge of
the Company, no other party to a License-In Agreement is in material default thereunder.
(c) Except as would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, the Company and its Subsidiaries own or have the right to use,
without payments to any other Person other than payments described in any agreement disclosed to
Parent, all Intellectual Property used in the operation of the business of the Company and its
Subsidiaries as and where the business is presently conducted. The Company and its Subsidiaries
have taken commercially reasonable actions required to maintain each item of Intellectual Property
that they own or use, except where the failure to take such actions would not reasonably be
expected to have a Company Material Adverse Effect.
27
(d) To the knowledge of the Company, except as would not individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect, the operation of the business of
the Company or any of its Subsidiaries as and where presently conducted does not infringe or
misappropriate, any Intellectual Property rights of third parties. Except as set forth in
Section 5.11(d) of the Company Disclosure Schedule, neither the Company nor any of its
Subsidiaries has received any written notice during the past two (2) years (or earlier, if not
resolved), alleging any such infringement or misappropriation (including any written claim that the
Company or any of its Subsidiaries must license or refrain from using any Intellectual Property
rights of any third party), excluding any of the forgoing that would not reasonably be expected to
have a Company Material Adverse Effect. To the knowledge of the Company, no third party has
infringed upon or misappropriated any Intellectual Property rights of the Company or any of its
Subsidiaries during the past two (2) years (or earlier if not resolved), excluding any such
infringement or misappropriation that would not reasonably be expected to have a Company Material
Adverse Effect.
(e) To the knowledge of the Company, as of the Effective Time, no former or current
stockholder, employee, director or officer of the Company or any of its Subsidiaries will have,
directly or indirectly, any material interest in any material Intellectual Property used in the
business of the Company and its Subsidiaries as and where presently conducted.
Section 5.12 Taxes.
(a) Each of the Company and its Subsidiaries has (i) timely filed all Tax Returns required to
be filed by any of them (taking into account applicable extensions) and all such returns were true,
correct and complete in all material respects when filed and (ii) paid or accrued (in accordance
with GAAP) all Taxes (whether or not such Taxes were shown to be due on any Tax Returns) other than
such Taxes as are being contested in good faith by the Company or its Subsidiaries;
(b) Except
as set forth in Section 5.12(b) of the Company Disclosure Schedule, there
are no pending federal, state, local or foreign audits or examinations of any Tax Return of the
Company or its Subsidiaries; any deficiencies proposed as a result of any audits of the Company or
Subsidiary have been paid or settled; and there are no material outstanding, pending or threatened Tax
claims, deficiencies, assessments or adjustments with respect to the Tax Returns of the Company or
its Subsidiaries;
(c) There are no outstanding written waivers to extend the statutory period of limitations
applicable to the assessment of any Taxes or deficiencies against the Company or any of its
Subsidiaries;
(d) Within the past five (5) years, no written inquiry or claim has been made by any
Governmental Entity in any jurisdiction in which the Company or any of its Subsidiaries does not
file a Tax Return that the Company or any of its Subsidiaries is or may be subject to taxation by
that jurisdiction and no such inquiry or claim exists which has not been resolved by a
determination by such Governmental Entity that the Company and its Subsidiaries are not so subject
to taxation;
(e) There are no liens for Taxes upon the assets of the Company or any of its Subsidiaries,
except for liens for current Taxes not yet due; and
(f) The Company has made available to Parent correct and complete copies of all Tax Returns,
examination reports, and statements of deficiencies assessed against or agreed to by the Company or
any of its Subsidiaries since 2007.
28
Section 5.13 Assets and Properties.
(a) Tangible Assets. Except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect, the Company and/or one or more of
its Subsidiaries has valid title to, or valid leasehold or sublease interests or other comparable
contract rights in or relating to, all of the real properties and other tangible assets necessary
for the conduct of the business of the Company and its Subsidiaries, taken as a whole, as currently
conducted.
(b) Real Property. Neither the Company nor any Subsidiary owns any real property.
Section 5.13(b) of the Company Disclosure Schedule sets forth the address of each Leased
Real Property and a complete and accurate list of all Leases (including all amendments, extensions,
renewals, guaranties and other agreements with respect thereto) for each such Leased Real Property
(including the date and name of the parties to such Lease). The Company has delivered or made
available to Parent a complete and correct copy of each such Lease. Except for matters that,
individually or in the aggregate would not have a Company Material Adverse Effect, with respect to
each of the Leases: (i) such Lease is legally valid and binding and enforceable against the Company
or the applicable Subsidiary in accordance with its terms, (ii) neither the Company nor any
Subsidiary nor, to the knowledge of the Company, the other party to any Lease is in breach or
default under such Lease, and, to the knowledge of the Company, no event has occurred or
circumstance exists which, with the delivery of notice, the passage of time or both, would
constitute such a breach or default, (iii) neither the Company nor any Subsidiary has subleased or
otherwise granted any Person the right to use or occupy the Leased Real Property or any portion
thereof, and (iv) the Leased Real Property comprises all of the real property used by the Company
and the Subsidiaries in the business of the Company and the Subsidiaries as currently conducted.
Except for matters that, individually or in the aggregate, would not have a Company Material
Adverse Effect, all buildings, structures, improvements, fixtures, building systems and equipment
and all components thereof included in the Leased Real Property are in good condition and repair
and sufficient for the operation of the businesses of the Company and the Subsidiaries as currently
conducted.
Section 5.14 Environmental.
(a) Each of the Company and its Subsidiaries is in compliance in all materials respects with
all Environmental Laws, which compliance includes the possession by the Company and its
Subsidiaries of material permits and other governmental authorizations required for their current
operations under applicable Environmental Laws, and compliance with the terms and conditions
thereof;
(b) Neither the Company nor any of its Subsidiaries has received written notice of any
Environmental Claims against the Company or any Subsidiary; and
(c) With respect to the real property currently owned, leased or operated by the Company or
any of its Subsidiaries, there have been no releases of Hazardous Materials by the Company, or to
the knowledge of the Company, by any other Person, that require a Cleanup.
Section 5.15 Labor Matters.
(a) Each of the Company and its Subsidiaries is in compliance with all applicable Laws
relating to labor, employment, termination of employment or similar matters and has not engaged in
any unfair labor practices or similar prohibited practices except in each case for any instance of
noncompliance that, individually or in the aggregate, have not had and could not reasonably be
expected to have a Company Material Adverse Effect.
29
(b) As of the date hereof, there are no pending or, to the knowledge of the Company,
threatened strikes, lockouts, work stoppages or slowdowns involving the employees of the Company or
any of its Subsidiaries, and neither the Company nor any of its Subsidiaries has experienced any
such strikes, lockouts, work stoppages or slowdowns within the past three (3) years that
individually or in the aggregate, have had or could reasonably be expected to have a Company
Material Adverse Effect.
(c) As of the date hereof, neither the Company nor any of its Subsidiaries is a party to, or
bound by, any collective bargaining agreement, contract or other agreement or understanding with a
labor union or labor organization, and, to the knowledge of the Company, there are no
organizational campaigns, petitions or other unionization activities seeking recognition of a
collective bargaining unit with respect to, or otherwise attempting to represent, any of the
employees of the Company or any of its Subsidiaries.
(d) There is no unfair labor practice or labor arbitration proceeding pending or, to the
knowledge of the Company, threatened against the Company or its Subsidiaries.
Section 5.16 FDA Regulatory Compliance.
(a) Except as set forth in Section 5.16(a) of the Company Disclosure Schedule, each product of
the Company that is subject to the U.S. Food, Drug and Cosmetic Act (including the rules and
regulations of the FDA promulgated thereunder, the “FDCA”) or comparable applicable Laws in
any non-U.S. jurisdiction (each such product, a “Medical Device”), is being or has been
developed, manufactured, sold, licensed, imported for resale, tested, processed, labeled, stored,
distributed and marketed in compliance, in all material respects, with all necessary Permits and
other applicable requirements under the FDCA and comparable applicable Laws in any non-U.S.
jurisdiction, including those relating to premarket clearance or approval, establishment
registration, device listing, quality system regulation, current Good Manufacturing Practices
(“cGMP”), labeling, advertising, record keeping and filing of required reports.
(b) All material reports, documents, claims, Permits and notices required to be filed,
maintained or furnished with or to the FDA or any other Governmental Entity by the Company have
been so filed, maintained or furnished. All such reports, documents, claims, Permits and notices
were complete and accurate in all material respects on the date filed (or were corrected in or
supplemented by a subsequent filing). All such reports, documents, claims, Permits and notices
have been provided or made available to Parent.
(c) Except as set forth in Section 5.16(c) of the Company Disclosure Schedule, the
Company has not received any FDA Form 483, notice of adverse finding, demand letters, warning
letters, or other correspondence or notice from the FDA, or other Governmental Entity (i) alleging
or asserting noncompliance with any applicable Laws or Permits; or (ii) contesting the premarket
clearance or approval of, the uses of or the labeling or promotion of any Medical Device.
(d) Except as set forth in Section 5.16(d) of the Company Disclosure Schedule, the
Permits issued to the Company by the FDA or any other Governmental Entity have not been limited,
suspended, or revoked. No medical device report (or its counterpart in non-U.S. jurisdictions)
with respect to any Medical Device has been reported by the Company to the FDA or other
Governmental Entity, and to the knowledge of the Company, no medical device report (or its
counterpart in non-U.S. jurisdictions) with respect to any Medical Device is under investigation by
the FDA or other Governmental Entity.
30
(e) Except as set forth in Section 5.16(e) of the Company Disclosure Schedule, the
Company has not voluntarily or involuntarily initiated, conducted or issued, or caused to be
initiated, conducted or issued, any recall, field notifications, field corrections, market
withdrawal or replacement, safety alert, warning, or “dear doctor” letter relating to an alleged
lack of safety, efficacy or regulatory compliance of any Medical Device.
(f) The Company has not received any written notice that the FDA or any other Governmental
Entity has (i) commenced, or threatened to initiate, any action to withdraw its premarket clearance
or premarket approval of any Medical Device; (ii) requested the recall of any Medical Device; (iii)
commenced, or threatened to initiate, any action to enjoin manufacture or distribution of any
Medical Device; or (iv) commenced, or threatened to initiate, any action to enjoin the manufacture
or distribution of any Medical Device produced at any facility where any Medical Device is
manufactured, tested, processed, packaged or held for sale.
(g) To the Company’s knowledge, the Company has not: (i) employed in any capacity any
individual who has been debarred pursuant to the FDCA; or (ii) committed any act, made any
statement or failed to make any statement that would breach the FDA’s policy with respect to
“Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities,” 56 Fed. Reg. 46191
(September 10, 1991), or any similar laws, rules, regulations or policies, whether under the
jurisdiction of the FDA or a similar entity in any other jurisdiction, and any amendments or other
modification thereto.
Section 5.17 Proxy Statement. The Proxy Statement, if any (and any amendment thereof
and supplement thereto), will not, at the date the Proxy Statement is first mailed to stockholders
of the Company or at the time of the Company Stockholders Meeting, contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which they were made, not
misleading, except that no representation or warranty is made by the Company with respect to
statements made or incorporated by reference therein based on information supplied by or on behalf
of Parent or Merger Sub for inclusion or incorporation by reference therein.
Section 5.18 Brokers or Finders. No investment banker, broker, finder, consultant or
intermediary other than Xxxxx Xxxxxxx & Co., the fees and expenses of which will be paid by the
Company, is entitled to any investment banking, brokerage, finder’s or similar fee or commission in
connection with this Agreement or the Transactions based upon arrangements made by or on behalf of
the Company or any of its Subsidiaries.
Section 5.19 Stockholders’ Rights Agreement. The Company has not adopted, and does not
intend to adopt, a stockholders rights agreement, “poison pill” or any similar plan or agreement
which limits or impairs the ability to purchase, or become the direct or indirect beneficial owner
of, shares or any other equity or debt securities of the Company.
Section 5.20 State Takeover Statutes. The Company Board has unanimously approved the
terms of this Agreement and the consummation of the Transactions, and such approval represents all
the actions necessary to render inapplicable to this Agreement and the Transactions, the
restrictions on “business combinations” set forth in the Delaware Takeover Statute or the
restrictions on “significant business transactions” set forth in the Washington Takeover Statute,
to the extent such restrictions would otherwise be applicable to this Agreement and the
Transactions. No other “moratorium”, “control share acquisition”, “fair price” or other form of
state takeover statute or similar state statute or regulation applies to this Agreement or the
Transactions.
31
Section 5.21 Insurance. Section 5.21 of the Company Disclosure Schedule sets
forth (a) a list of the material policies of insurance currently maintained by the Company or any
of its Subsidiaries (including material policies of insurance maintained for purposes of providing
benefits such as workers’ compensation and employers’ liability coverage) pursuant to which the
Company or any of its
Subsidiaries is a named insured or is otherwise a beneficiary and (b) a list of all material
claims currently pending under such policies of insurance (including with respect to insurance
obtained but not currently maintained). Except for those matters that, materially or in the
aggregate, have not had and could not reasonably be expected to have a Company Material Adverse
Effect, to the knowledge of the Company, (y) all such policies are in full force and effect and
cover the assets and risks of the Company and its Subsidiaries in a manner consistent with
customary practices of companies engaged in businesses and operations similar to those of the
Company and its Subsidiaries and (z) all premiums due on such policies have been paid and no notice
of cancellation or termination or intent to cancel has been received by the Company or any of its
Subsidiaries with respect to such policies.
Section 5.22 Related Party Transactions. Except to the extent disclosed under the
headings “Certain Relationships and Related Person Transactions” in the Company SEC Reports, there
are and have been no transactions, agreements, arrangements or understandings involving the Company
or its Subsidiaries that would be required to be disclosed under Item 404 of Regulation S-K under
the Exchange Act.
Section 5.23 Inventory. All inventory of the Company and its Subsidiaries consists of
a quality and quantity usable and salable in the ordinary course of business consistent with past
practice, subject to normal and customary reserves and allowances in accordance with GAAP and
consistent with past practice, which items have been written off or written down to fair market
value or for which adequate reserves have been provided in the Company’s financial statements as of
and for the period ended September 30, 2010.
Section 5.24 Accounts Receivable. All accounts receivable of the Company reflected in
the financial statements for the period ended September 30, 2010 arose from bona fide sales
transactions in the ordinary course of business. The Company has good title to all of its accounts
receivable free and clear of all liens other than Permitted Liens or as set forth in Section
5.24 of the Company Disclosure Schedule.
Section 5.25 Ethical Practices. Except as permitted under applicable Law, neither the
Company nor any of its Subsidiaries has offered or given anything of value to any official of a
Governmental Entity, any political party or official thereof, or any candidate for political office
(a) with the intent of inducing such Person to use such person’s influence with any Governmental
Entity to affect or influence any act or decision of such Governmental Entity to assist the Company
or any of its Subsidiaries in obtaining or retaining business for, or with, or directing business
to, any Person or (b) which constitutes a bribe, kickback or illegal or improper payment to assist
the Company or any of its Subsidiaries in obtaining or retaining business for or with any
Governmental Entity.
ARTICLE VI
REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB
REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB
Parent and Merger Sub jointly and severally represent and warrant to the Company as follows:
Section 6.1 Organization. Each of Parent and Merger Sub is a corporation duly
organized, validly existing and in good standing under the laws of the jurisdiction of its
32
incorporation and has the requisite power and authority to own, lease and operate its properties
and to carry on its business as it is now being conducted. Each of Parent and Merger Sub is duly
qualified or licensed to do business and in good standing in each jurisdiction in which the
property owned, leased or operated by it or the nature of the business conducted by it makes such
qualification or licensing
necessary, except where the failure to be so duly qualified or licensed and in good standing
would not, individually or in the aggregate, have a Parent Material Adverse Effect. Parent has
made available to the Company a copy of the certificate of incorporation and bylaws or other
equivalent organizational documents of Parent and Merger Sub, as currently in effect, and neither
Parent nor Merger Sub is in violation of any provision of its certificate of incorporation or
bylaws or other equivalent organizational documents.
Section 6.2 Authorization; Validity of Agreement; Necessary Action.
(a) Each of Parent and Merger Sub has the requisite power and authority to execute and deliver
this Agreement and to consummate the Transactions. The execution, delivery and performance by
Parent and Merger Sub of this Agreement, approval and adoption of this Agreement and the
consummation of the Transactions have been duly and validly authorized by all necessary action of
Parent and Merger Sub, and no other action on the part of Parent or Merger Sub is necessary to
authorize the execution and delivery by Parent and Merger Sub of this Agreement and the
consummation by them of the Transactions. This Agreement has been duly executed and delivered by
Parent and Merger Sub and, assuming due and valid authorization, execution and delivery hereof by
the Company, is a valid and binding obligation of each of Parent and Merger Sub, enforceable
against each of them in accordance with its terms, except that (i) such enforcement may be subject
to applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or
hereafter in effect, affecting creditors’ rights generally and (ii) the remedy of specific
performance and injunctive and other forms of equitable relief may be subject to equitable defenses
and to the discretion of the court before which any proceeding therefor may be brought.
(b) The board of directors of Parent has properly and validly authorized and approved this
Agreement and the Transactions in accordance with applicable Law.
(c) The board of directors of Merger Sub, at a meeting duly called and held (or acting by
written consent) duly and unanimously adopted resolutions (i) approving this Agreement and the
Transactions, (ii) determining that the terms of the Transactions are fair to and in the best
interests of Merger Sub, its stockholder and Parent as the parent of Merger Sub, and (iii)
recommending that the sole stockholder of Merger Sub, approve and adopt this Agreement
and the Merger.
(d) The stockholder of Merger Sub has unanimously adopted and approved this Agreement and the
Transactions upon the terms and subject to the conditions set forth herein.
Section 6.3 Consents and Approvals; No Violations. The execution and delivery of this
Agreement by Parent and Merger Sub do not, and the performance by Parent and Merger Sub of this
Agreement and the consummation by Parent and Merger Sub of the Transactions will not, (i) violate
any provision of the certificate of incorporation or bylaws (or equivalent organizational
documents) of Parent or Merger Sub, (ii) result in a violation or breach of, or constitute (with or
without due notice or lapse of time or both) a default (or give rise to any right of termination,
cancellation or acceleration) under, any of the terms, conditions or provisions of any note, bond,
mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which
Parent or any of its Subsidiaries is a party or by which any of them or any of their properties or
assets may be bound, (iii) violate any Law applicable to Parent, any of its Subsidiaries or any of
their properties or assets or (iv) other than in connection with or compliance with (A) the DGCL,
(B) requirements under other state
33
corporation Laws, (C) the HSR Act, if applicable, and any
applicable competition, antitrust or investment Laws of jurisdictions other than the U. S., and (D)
the Exchange Act, including without limitation, the filing with the SEC of the Schedule TO, require
on the part of Parent or Merger Sub any filing or registration with, notification to, or
authorization, consent or approval of, any Governmental Entity.
Section 6.4 Litigation. There is no action, claim, suit or proceeding pending or, to
the knowledge of Parent and Merger Sub, threatened, that would, individually or in the aggregate,
reasonably be expected to affect Parent or Merger Sub or their respective assets or businesses.
Section 6.5 Ownership of Capital Stock. None of Parent, Merger Sub or their
respective Affiliates are or ever have been, with respect to the Company, an “interested
stockholder” as such term is defined in the Delaware Takeover Statute or an “acquiring person” as
such term is defined in the Washington Takeover Statute, and none of them have taken any action
that would cause any antitakeover statute to apply to the Transactions.
Section 6.6 Compliance with Law. Except as would not, individually or in the
aggregate, have a Parent Material Adverse Effect, neither Parent nor any of its Subsidiaries is in
violation of, or in default under, any Law, in each case, applicable to Parent or any of its
Subsidiaries or any of their respective assets and properties.
Section 6.7 Merger Sub’s Operations. Merger Sub was formed solely for the purpose of
engaging in the Transactions and has not owned any assets, engaged in any business activities or
conducted any operations other than in connection with the Transactions.
Section 6.8 Proxy Statement. None of the information supplied by Parent or Merger Sub
for inclusion in the Proxy Statement, if any (and any amendment thereof and supplement thereto),
will, at the date the Proxy Statement is first mailed to stockholders of the Company or at the time
of the Company Stockholders Meeting, contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading, except that no
representation is made with respect to statements made or incorporated by reference therein based
on information supplied by or on behalf of the Company if an inclusion or incorporation by
reference therein.
Section 6.9 Sufficient Funds. Parent currently has available to it, and will cause
Merger Sub to have (i) at the Offer Closing Date, sufficient immediately available funds (through
existing credit arrangements or otherwise) to pay the Offer Price for all shares of Common Stock
tendered into the Offer, subject to the terms and conditions of the Offer and this Agreement and
(ii) at the Effective Time, sufficient immediately available funds (through existing credit
arrangements or otherwise), to pay in full the Merger Consideration, Option Consideration and RSU
Consideration and to pay when due all of its fees and expenses related to the Transactions, subject
to the terms and conditions of this Agreement.
Section 6.10 Brokers or Finders. No investment banker, broker, finder, consultant or
intermediary, is entitled to any investment banking, brokerage, finder’s or similar fee or
commission in connection with this Agreement or the Transactions based upon arrangements made by or
on behalf of Parent or any of its Subsidiaries.
ARTICLE VII
COVENANTS
COVENANTS
Section 7.1 Interim Operations of the Company. During the period from the date of
this Agreement until the earlier of (a) such time as designees of Parent first constitute at least
a
34
majority of the Company Board pursuant to Section 2.4(a), (b) the Effective Time and (c)
the date, if any, on which this Agreement is earlier terminated pursuant to Section 9.1
(except (x) as may be required by Law, (y) with the prior written consent of Parent (provided that
Parent shall be deemed to have consented if Parent does not object within seventy-two (72) hours
after a written request for such consent is delivered to Parent by the Company), which consent
shall not be unreasonably withheld, delayed or
conditioned, or (z) as contemplated or permitted by this Agreement, the business of the
Company and its Subsidiaries shall be conducted only in the ordinary and usual course of business
in all material respects consistent with past practice, and, to the extent consistent therewith,
the Company and its Subsidiaries shall use commercially reasonable efforts to (1) preserve intact
their current business organization and (2) preserve their relationships with customers, suppliers
and others having business dealings with them; provided, however, that no action by the Company or
any of its Subsidiaries with respect to matters addressed specifically by any provision of this
Section 7.1 shall be deemed a breach of this sentence unless such action would constitute a
breach of such specific provision. Without limiting the generality of the foregoing, except (A) as
may be required by Law, (B) with the prior written consent of Parent (provided that Parent shall be
deemed to have consented if Parent does not object within seventy-two (72) hours after a written
request for such consent is delivered to Parent by the Company), which consent shall not be
unreasonably withheld, delayed or conditioned, or (C) as contemplated or permitted by this
Agreement, until the earlier of (1) such time as designees of Parent first constitute at least a
majority of the Company Board pursuant to Section 2.4(a), (2) the Effective Time and (3)
the date, if any, on which this Agreement is earlier terminated pursuant to Section 9.1,
neither the Company nor any of its Subsidiaries will:
(a) amend its certificate of incorporation or bylaws (or equivalent organizational documents);
(b) except for Common Stock to be issued or delivered pursuant to the exercise of Options
outstanding on the date hereof under the Company Equity Plans or the ESPP, issue, deliver, sell,
dispose of, pledge or otherwise encumber, or authorize or propose the issuance, sale, disposition
or pledge or other encumbrance of (i) any shares of capital stock of any class or any other
ownership interest of the Company or any of its Subsidiaries, or any securities or rights
convertible into, exchangeable for, or evidencing the right to subscribe for any shares of capital
stock or any other ownership interest of the Company or any of its Subsidiaries, or any rights,
warrants, options, calls, commitments or any other agreements of any character to purchase or
acquire any shares of capital stock or any other ownership interest of the Company or any of its
Subsidiaries or any securities or rights convertible into, exchangeable for, or evidencing the
right to subscribe for, any shares of capital stock or any other ownership interest of the Company
or any of its Subsidiaries, or (ii) any other securities of the Company or any of its Subsidiaries
in respect of, in lieu of, or in substitution for, Common Stock outstanding on the date hereof;
(c) redeem, purchase or otherwise acquire, or propose to redeem, purchase or otherwise
acquire, any outstanding Common Stock;
(d) split, combine, subdivide or reclassify any Common Stock or declare, set aside for payment
or pay any dividend or other distribution in respect of any Common Stock or otherwise make any
payments to stockholders in their capacity as such;
(e) adopt a plan of complete or partial liquidation, dissolution, merger, consolidation,
restructuring, recapitalization or other reorganization of the Company or any of its Subsidiaries,
other than the Merger;
35
(f) acquire, sell, lease, dispose of, pledge or encumber any assets that, in the aggregate,
are material to the Company and its Subsidiaries, taken as a whole (other than the sale of
inventory in the ordinary course of business);
(g) incur any material indebtedness for borrowed money in addition to that incurred as of the
date of this Agreement or guarantee any such indebtedness or make any loans, advances
or capital contributions to, or investments in, any other Person, other than to the Company or
any wholly owned Subsidiary of the Company (other than borrowings);
(h) grant any increases in the compensation of its directors, officers or key employees,
except in the ordinary course of business, or enter into any new employment or severance protection
agreements with any such directors, officers or key employees;
(i) except as may be contemplated by this Agreement or in the ordinary course of business,
terminate or amend any Benefit Plans;
(j) change any of the accounting methods used by the Company unless required by GAAP or
applicable Law;
(k) except as set forth in Schedule 7.1(k), make, or agree to make, any capital expenditures
in excess of Fifty Thousand US Dollars ($50,000);
(l) settle or compromise any material claim by or against the Company;
(m) allow any insurance maintained by the Company to cease being in full force and effect; or
(n) take any action which would cause the conditions to the Closing to not be satisfied.
Section 7.2 Access to Information. The Company shall (and shall cause each of its
Subsidiaries to) afford to Representatives of Parent reasonable access, in a manner not disruptive
to the operations of the business of the Company and its Subsidiaries, during normal business hours
and upon reasonable notice throughout the period prior to the Effective Time, to the properties,
books and records of the Company and its Subsidiaries; provided, however, that nothing herein shall
require the Company or any of its Subsidiaries to disclose any information to Parent or Merger Sub
if such disclosure would, in the reasonable judgment of the Company, (a) cause significant
competitive harm to the Company or its Subsidiaries if the Transactions are not consummated, (b)
violate applicable Law or the provisions of any agreement to which the Company or any of its
Subsidiaries is a party or (c) jeopardize any attorney-client or other legal privilege; provided
further, however, that nothing herein shall authorize Parent or its Representatives to undertake
any further investigation of the Company, including environmental investigations or sampling at any
of the properties owned, operated or leased by the Company or its Subsidiaries. The Mutual
Non-Disclosure Agreement, dated July 25, 2010 (the “Non-Disclosure Agreement”),
between the Company and Parent shall apply with respect to information furnished by the Company,
its Subsidiaries and the Company’s officers, employees, and other Representatives hereunder.
Section 7.3 Acquisition Proposals.
(a) Subject to Section 7.3(b), from the date hereof until the Effective Time or, if
earlier, the termination of this Agreement in accordance with Article IX, the Company shall
not, nor
36
shall it permit any of its Subsidiaries to, nor shall it authorize or permit any of its
Representatives to, directly or indirectly through another Person, (i) solicit, initiate or
knowingly encourage (including by way of furnishing information, except information relating to the
existence of these provisions), or take any other action designed to facilitate, directly or
indirectly, any inquiries or the making of any Acquisition Proposal or (ii) participate in any
discussions (except as to the existence of these provisions) or negotiations relating to any
Acquisition Proposal. Subject to Section 7.3(b), from the date hereof the
Company shall cease and cause to be terminated any solicitation, encouragement, discussion or
negotiation with any Persons conducted theretofore by the Company, its Subsidiaries or any of their
respective Representatives with respect to any Acquisition Proposal. The Company shall promptly
after the date of this Agreement instruct each Person which has heretofore executed a
confidentiality agreement relating to any Acquisition Proposal with or for the benefit of the
Company to promptly return or destroy all information, documents and materials relating to an
Acquisition Proposal or the Company or its businesses, operations or affairs heretofore furnished
by the Company or any of its Representatives to such Person or any of its Representatives in
accordance with the terms of any confidentiality agreement with such Person.
(b) Notwithstanding anything to the contrary contained in Section 7.3(a) if at any
time prior to the Offer Closing, the Company receives an unsolicited bona fide written Acquisition
Proposal from a third party which the Company Board determines constitutes or could reasonably be
likely to result in a Superior Proposal, the Company may, in response to such Acquisition Proposal
(provided such Acquisition Proposal did not result from a breach by the Company of Section
7.3(a), Section 7.3(b) or Section 7.3(c)), (A) furnish information with respect
to the Company and its Subsidiaries to any Person making such Acquisition Proposal pursuant to a
customary confidentiality agreement (as determined after consultation with its outside counsel) (an
“Acceptable Confidentiality Agreement”), the benefits of the terms of which, if more
favorable to the other party to such confidentiality agreement than those in place with Parent,
shall be extended to Parent and the Company shall simultaneously provide Parent a copy of all
information furnished to such Person to the extent it has not previously been so furnished to
Parent, and (B) participate in discussions and negotiations regarding such Acquisition Proposal.
From and after the date hereof, except as restricted by a confidentiality agreement or similar
obligation in effect as of the date hereof by which the Company is bound, if the Company has
received an Acquisition Proposal, it shall promptly advise Parent orally and in writing of such
Acquisition Proposal, any request for information, and the material terms and conditions of such
request or Acquisition Proposal, and shall keep Parent reasonably informed of the status and
details of any such Acquisition Proposal.
(c) Except as expressly permitted by this Section 7.3(c), neither the Company Board,
nor any committee thereof shall (i) withdraw or modify, or propose publicly to withdraw or modify,
in a manner adverse to Parent or Merger Sub, the approval or recommendation by the Company Board of
this Agreement or the Transactions or the approval of this Agreement by the stockholders at the
Company Stockholders Meeting (a “Change of Recommendation”), (ii) approve or recommend, or
propose publicly to approve or recommend, any Acquisition Proposal other than this Agreement, or
(iii) cause or permit the Company to enter into any letter of intent, agreement in principle,
acquisition agreement or other similar agreement or understanding (an “Acquisition
Agreement”) related to any Acquisition Proposal. Notwithstanding the foregoing, prior to the
Offer Closing , (i) in response to the receipt of a written Acquisition Proposal (that has not been
withdrawn) in connection with which the Company has not breached Section 7.3(a) (subject to
Section 7.3(b)), if the Company Board determines that such Acquisition Proposal is a
Superior Proposal, then the Company Board may approve or recommend such Superior Proposal and, in
connection with the approval or recommendation of such Superior Proposal, make a Change of
Recommendation and/or terminate this Agreement (and subject to Article IX, including payment of the
Termination Fee, in connection with such termination, if it so chooses, cause the Company to enter
into an Acquisition Agreement with respect to such Superior
37
Proposal); provided that: (A) prior to
the Company entering into an Acquisition Agreement to effect such Superior Proposal, the Company
shall have provided to Parent prompt written notice advising Parent of the decision of the Company
Board to take such action and the reasons therefor, including the material terms and conditions of
the Acquisition Proposal; (B) the Company shall have given Parent five (5) Business Days after
delivery of such notice to propose revisions to the terms of this Agreement (or make another
proposal) and if Parent proposes to revise the terms of this Agreement or make another proposal,
the Company shall have, during such period, negotiated in good faith with Parent with respect
to such proposed revisions or other proposal (it being agreed that any material changes to any
Acquisition Proposal shall require a new notice and a new five (5) Business Day period for
negotiations) and (C) the Company Board shall have determined in good faith, after considering the
results of such negotiations and giving effect to the proposals made by Parent, if any, that such
Acquisition Proposal constitutes a Superior Proposal and that the failure to take such action would
be inconsistent with the fiduciary duties of the Company Board to the Company’s stockholders under
applicable Law and (ii) other than in connection with an Acquisition Proposal, if the Company Board
determines in good faith, after consultation with its legal counsel, that its failure to take such
actions would be reasonably likely to be inconsistent with its fiduciary duties to the stockholders
of the Company under applicable Law, then the Company Board may make a Change of Recommendation.
(d) Nothing in this Section 7.3 shall prohibit the Company Board from taking and
disclosing to the Company’s stockholders a position contemplated by Rule 14e 2(a), Rule 14D-9 or
Item 1012(a) of Regulation M-A promulgated under the Exchange Act, or other applicable law
(including, without limitation, any amendments to its Schedule 14D-9 relating to a Change of
Recommendation) if the Company Board determines, after consultation with outside counsel, that
failure to so disclose such position could constitute a violation of applicable law and any such
disclosure which would otherwise constitute a withdrawal, change or modification of the approval or
recommendation of the Company Board, shall not be deemed to constitute such a withdrawal, change or
modification with respect to the Merger for the purposes of Section 7.3(c) if the Company
Board expressly publicly reaffirms its approval and recommendation of this Agreement within five
(5) Business Days after a request by Parent to do so. In addition, it is understood and agreed
that, for purposes of this Section 7.3, a factually accurate public statement by the
Company that describes the Company’s receipt of an Acquisition Proposal and the operation of this
Agreement with respect thereto and contains a “stop-look-and-listen” communication shall not
constitute a withdrawal, change or modification of the approval or recommendation of the Company
Board with respect to the Transactions for the purposes of Section 7.3(c).
Section 7.4 Employee Benefits.
(a) As of the Effective Time, and for a period of at least one (1) year thereafter, Parent
agrees to (i) provide or cause its Subsidiaries (including the Surviving Corporation) to provide
each of the employees of the Company and its Subsidiaries (the “Employees”) with base
salary or wage rates and other cash compensation that, in the aggregate, are substantially
comparable to those in effect for such Employee immediately prior to the Effective Time and (ii)
either (A) maintain or cause its Subsidiaries (including the Surviving Corporation) to maintain the
Benefit Plans at the benefit levels in effect on the date hereof or (B) provide or cause its
Subsidiaries (including the Surviving Corporation) to provide employee benefits (including, without
limitation, retirement, health and life insurance benefits but excluding equity based benefits)
that, in the aggregate, are substantially comparable to each Employee (and such Employee’s spouse
and dependents) to those in effect under the Benefit Plan for such Employee (and his or her spouse
and dependents) immediately prior to the Effective Time.
(b) As of the Effective Time, Parent shall honor or cause to be honored, in accordance with
their terms, all Benefit Agreements and all incentive, bonus, individual benefit,
38
employment,
employment termination, severance and other compensation agreements, plans and arrangements,
including the Company’s executive change-in-control and general severance and retention plans
(collectively, the “CIC Plans”), in each case existing immediately prior to the execution
of this Agreement, that are between the Company or any of its Subsidiaries and any current or
former officer, director or employee thereof or for the benefit of any such current or former
officer, director or employee,
provided that the foregoing shall not apply to any officer, director or employee who has
entered into or will enter into an individual agreement with Parent or Parent’s Subsidiaries.
(c) Parent shall treat, and shall cause each benefit plan, program, practice, policy and
arrangement maintained by Parent or its Subsidiaries (including the Surviving Corporation) or
Affiliates following the Effective Time and in which any of the Employees participate or are
eligible to participate (the “Parent Plans”) to treat, for purposes of determining
eligibility to participate, vesting, accrual of and entitlement to benefits (but not for accrual of
benefits under any “pension plan,” as defined in Section 3(2) of ERISA) and all other purposes, all
service with the Company and its Subsidiaries (or predecessor employers to the extent the Company
or any Benefit Plan provides past service credit) as service with Parent and its Subsidiaries;
provided, however, that such service shall not be recognized to the extent that such recognition
would result in a duplication of benefits with respect to the same period of service or with
respect to newly implemented plans for which prior service is not taken into account or with
respect to plans for which participation, service and/or benefit accrual is frozen. Parent shall
cause each Parent Plan that is a welfare benefit plan, within the meaning of Section 3(1) of ERISA,
(i) to waive any and all eligibility waiting periods, evidence of insurability requirements and
pre-existing condition limitations to the extent waived, satisfied or not included under the
corresponding Benefit Plan, and (ii) to recognize for each Employee for purposes of applying annual
deductible, co-payment and out-of-pocket maximums under such Parent Plan any deductible, co-payment
and out-of-pocket expenses paid by the Employee and his or her spouse and dependents under a
corresponding Benefit Plan during the calendar year in which occurs the later of the Effective Time
and the date on which the Employee begins participation in such Parent Plan.
(d) This Section 7.4 shall be binding upon and inure solely to the benefit of each
party to this Agreement, and nothing in this Section 7.4, express or implied, is intended
to confer upon any other Person, including, any current or former director, officer or employee of
the Company or any Company Subsidiary, any rights or remedies of any nature whatsoever under or by
reason of this Section 7.4.
Section 7.5 Publicity. The initial press release by each of Parent and the Company
with respect to the execution of this Agreement shall be acceptable to Parent and the Company.
During the period between the date of this Agreement and the earlier of the Offer Closing and the
termination of this Agreement in accordance with Section 9.1, neither the Company nor
Parent (nor any of their respective Affiliates) shall issue any other press release or make any
other public announcement with respect to this Agreement or the Transactions without the prior
agreement of the other party, except as may be required by Law or by any listing agreement with a
national securities exchange, in which case the party proposing to issue such press release or make
such public announcement shall use its reasonable efforts to consult in good faith with the other
party before making any such public announcements; provided that the Company will no longer be
required to obtain the prior agreement of or consult with Parent in connection with any such press
release or public announcement if the Company Board has effected a Change of Recommendation or in
connection with any such press release or public announcement pursuant to Section 7.3(c).
Section 7.6 Directors’ and Officers’ Insurance and Indemnification.
39
(a) From and after the Effective Time, Parent shall, and shall cause the Surviving Corporation
to, indemnify and hold harmless the individuals who at any time prior to the Effective Time were
directors or officers of the Company or any of its present or former Subsidiaries or corporate
parents (the “Indemnified Parties”) against any costs or expenses (including reasonable
attorneys’ fees), judgments, fines, losses, claims, damages or liabilities in connection with
actions or omissions occurring at or prior to the Effective Time (including the Transactions) to
the fullest extent
permitted by and subject to the limitations in applicable Law, and Parent shall, and shall
cause the Surviving Corporation to, promptly advance expenses as incurred to the fullest extent
permitted by Law. The provisions relating to indemnification in the certificate of incorporation
or bylaws of the Surviving Corporation will not be amended, repealed or modified after the
Effective Time in any manner that would materially adversely affect the rights thereunder of the
Indemnified Parties, unless such modification is required by Law.
(b) Parent shall cause to be maintained in effect for not less than six (6) years from the
Effective Time the current policies of directors’ and officers’ liability insurance and fiduciary
liability insurance maintained by the Company and the Company’s Subsidiaries for the Indemnified
parties and any other employees, agents or other individuals otherwise covered by such insurance
policies prior to the Effective Time (collectively, the “Insured Parties”) with respect to
matters occurring at or prior to the Effective Time (including the Transactions); provided that, in
lieu of the purchase of such insurance by Parent or the Surviving corporation, the Company may at
its option prior to the Effective Time purchase a six-year extended reporting period or “tail”
policy for directors’ and officers’ liability insurance and fiduciary liability insurance providing
at least the same coverage with respect to matters occurring at or prior to the Effective Time.
(c) This Section 7.6 is intended to benefit the Indemnified Parties, and shall be
binding on all successors and assigns of Parent, Merger Sub, the Company and the Surviving
Corporation.
(d) In the event that Parent, the Surviving Corporation or any of their successors or assigns
(i) consolidates with or merges into any other Person and shall not be the continuing or surviving
Person of such consolidation or merger or (ii) transfers or conveys a majority of its properties
and assets to any Person, then, and in each such case, proper provision shall be made so that the
successors, assigns and transferees of Parent or the Surviving Corporation or their respective
successors or assigns, as the case may be, assume the obligations set forth in this Section
7.6.
Section 7.7 Proxy Statement; Stockholders Meeting.
(a) If the adoption of this Agreement by the stockholders of the Company is required by the
DGCL, so long as the Company Board shall not have effected a Change of Recommendation, (a) the
Company shall take all action necessary in accordance with applicable Law and its certificate of
incorporation and bylaws and the Nasdaq Marketplace Rules to call, give notice of, convene and hold
a meeting of the Company’s stockholders (including any adjournment or postponement thereof, the
“Company Stockholders Meeting”) as soon as is reasonably practicable following the Offer
Closing for the purpose of approving this Agreement, and (b) in connection with the Company
Stockholders Meeting, as soon as is reasonably practicable following the Offer Closing the Company
shall prepare and file with the SEC a proxy statement (together with all amendments and supplements
thereto, the “Proxy Statement”) relating to the Merger and this Agreement and furnish the
information required to be provided to the stockholders of the Company pursuant to the DGCL and the
Exchange Act; provided, that, if upon the date initially fixed for the Company Stockholders
Meeting, the conditions set forth in Section 8.1(b) and Section 8.1(c) have not
been met, the Company may reschedule or adjourn the Company Stockholders Meeting to such later date
as the Company, in its reasonable discretion, considers
40
to be more proximate to the probable
satisfaction of such conditions. Parent will provide the Company with any information which may be
required in order to effectuate the preparation and filing of the Proxy Statement. Promptly after
its preparation and prior to its filing with the SEC, the Company shall provide a copy of the Proxy
Statement, and any amendment to the Proxy Statement, to Parent, and will consider inclusion into
the Proxy Statement comments timely received from Parent or its counsel. The Company shall give
Parent notice of any comments on the Proxy Statement received by the SEC, and shall
promptly respond to SEC comments, if any. So long as the Company Board shall not have
effected a Change of Recommendation, the Proxy Statement shall include the recommendation of the
Company Board that the Company’s stockholders approve this Agreement (the “Company
Recommendation”).
(b) At the Company Stockholders Meeting or any postponement or adjournment thereof, Parent
shall vote, or cause to be voted, all of the shares of Common Stock then owned of record by Parent
or Merger Sub in favor of the adoption of this Agreement and approval of the Merger, and Parent
shall use its reasonable best efforts to deliver or provide (or cause to be delivered or provided),
in its capacity as a stockholder of the Company, any other approvals that are required by
applicable Law to effect the Merger.
(c) Notwithstanding the foregoing, if following the Offer and any subsequent offering period,
Parent and its Subsidiaries shall own at least ninety percent (90%) of the outstanding shares of
the Common Stock (the “Short-Form Threshold”), the parties hereto shall take all necessary
and appropriate action, including with respect to the transfer to Merger Sub of any shares of
Common Stock held by Parent or any Subsidiary of Parent, to cause the Merger to become effective as
soon as practicable after the Offer Closing without the Company Stockholder Meeting in accordance
with Section 253 of the DGCL.
Section 7.8 Best Efforts.
(a) Upon the terms and subject to the conditions set forth in this Agreement, the Company and
Parent shall each use their reasonable best efforts to promptly (i) take, or to cause to be taken,
all actions, and to do, or to cause to be done, and to assist and cooperate with the other parties
in doing all things necessary, proper or advisable under applicable Law or otherwise to consummate
and make effective the Transactions; (ii) obtain from any Governmental Entities any actions,
non-actions, clearances, waivers, consents, approvals, permits or orders required to be obtained by
the Company, Parent or any of their respective Subsidiaries in connection with the authorization,
execution, delivery and performance of this Agreement and the consummation of the Transactions;
(iii) promptly make all necessary registrations and filings, and thereafter make any other required
submissions, with respect to this Agreement and the Merger (A) required under any applicable
federal or state securities Laws, (B) required under any applicable competition, antitrust or
investment Laws of jurisdictions other than the U.S., (C) required under any other applicable Law;
provided, however, that the Company and Parent will cooperate with each other in connection with
the making of all such filings, including providing copies of all such filings and attachments to
outside counsel for the non-filing party; (iv) furnish all information required for any application
or other filing to be made pursuant to any applicable Law in connection with the Transactions; (v)
keep the other party informed in all material respects of any material communication received by
such party from, or given by such party to, any Governmental Entity and of any material
communication received or given in connection with any proceeding by a private party, in each case
relating to the Transactions; (vi) permit the other parties to review any material communication
delivered to, and consult with the other parties in advance of any meeting or conference with, any
Governmental Entity relating to the Transactions or in connection with any proceeding by a private
party relating thereto, and giving the other party the opportunity to attend and participate in
such meetings and conferences; (vii) avoid the entry of, or have vacated or terminated, any decree,
order, or judgment that would restrain, prevent or delay the Closing, including defending any
lawsuits or other legal proceedings,
41
whether judicial or administrative, challenging this Agreement
or the consummation of the Transactions; and (viii) execute and deliver any additional instruments
necessary to consummate the Transactions.
(b) Each of the Company, on the one hand, and Parent and Merger Sub, on the other hand, shall
give prompt notice to the other of any written notice or other communication from any Governmental
Entity in connection with the Transactions.
Section 7.9 No Control of Other Party’s Business. Nothing contained in this Agreement
shall give Parent, directly or indirectly, the right to control or direct the Company’s operations
prior to the Offer Closing Date, and nothing contained in this Agreement shall give the Company,
directly or indirectly, the right to control or direct Parent’s or its Subsidiaries’ operations
prior to the Offer Closing Date. Prior to the Offer Closing Date, each of the Company and Parent
shall exercise, consistent with the terms and conditions of this Agreement, complete control and
supervision over its respective operations.
Section 7.10 Rule 14d-10 Matters. Notwithstanding anything in this Agreement to the
contrary and subject in any event to the provisions of Section 7.1(b), the Company will
not, on or after the date hereof and prior to the Offer Closing, enter into, establish, amend or
modify any plan, program, agreement or arrangement pursuant to which compensation is paid or
payable, or pursuant to which benefits are provided, in each case to any former, current or future
director, officer or employee of the Company (or any person who would have assumed such role or
performed such duties but for a requirement to refrain from assuming such role or performing such
duties in such plan, program, agreement or arrangement) unless, prior to such entry into,
establishment, amendment or modification, the Compensation Committee of the Company Board (each
member of which shall be an “independent director” in accordance with the requirements of Rule
14d-10(d)(2) under the Exchange Act at the time of any such action) shall have taken all such steps
as may be necessary to (i) approve as an employment compensation, severance or other employee
benefit arrangement each such plan, program, agreement or arrangement and (ii) satisfy the
requirements of the non-exclusive safe harbor under Rule 14d-10(d)(2) under the Exchange Act with
respect to such plan, program, agreement or arrangement. The Company shall, prior to the Offer
Closing, take such actions necessary and appropriate to ratify, confirm and approve, in accordance
with and for the purpose of Rule 14d-10 under the Exchange Act, compensation paid or payable to any
directors, officers or employees under any Benefit Plan or Benefit Agreement or otherwise in
connection with the Transactions.
Section 7.11 Rule 16b-3. Prior to the Offer Closing, the Company shall use reasonable
best efforts to cause any dispositions of Common Stock (including derivative securities with
respect to Common Stock) resulting from the Transactions by each individual who is subject to the
reporting requirements of Section 16(a) of the Exchange Act with respect to the Company to be
exempt under Rule 16b-3 promulgated under the Exchange Act.
Section 7.12 Delisting. The Company agrees to use its reasonable best efforts to (a)
delist the Company Common Stock from Nasdaq and (b) to terminate the registration of the Company
Common Stock under the Exchange Act; provided that such delisting or termination shall not be
effective until after the Effective Time. The Parent will use its reasonable best efforts to cause
the Surviving Corporation to file with the SEC (x) a Form 25 on the Closing Date and (y) a Form 15
on the first Business Day that is at least ten (10) days after the date the Form 25 is filed (such
period between the Form 25 filing date and the Form 15 filing date, the “Delisting
Period”). If the Surviving Corporation is reasonably likely to be required to file any reports
pursuant to the Exchange Act during the Delisting Period, the Company will deliver to the Parent at
least five (5) Business Days prior to the Closing a substantially final draft of any such reports
reasonably likely to be required to be filed during the Delisting Period (“Post-Closing SEC
Reports”). The Post-Closing SEC Reports provided by the Company
42
pursuant to this Section
7.12 will (1) not contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements made therein, in
the light of the circumstances under which they were made, not misleading and (2) comply in all
material respects with the provisions of applicable Laws.
Section 7.13 Withholding. Parent, Merger Sub, and the Paying Agent shall be entitled
to deduct and withhold from the consideration otherwise payable pursuant to this Agreement to
any holder of shares of Common Stock, Options, or RSUs such amounts as Parent, Merger Sub, or
the Paying Agent, as applicable, is required to deduct and withhold with respect to the making of
such payment under the Code or applicable Treasury regulations, or any other provision of Tax Law.
To the extent that amounts are so withheld and paid over by Parent, Merger Sub or the Paying Agent,
as applicable, to the appropriate taxing authority, such withheld amounts shall be treated for all
purposes as having been paid to the holder of the shares of Common Stock, Options, or RSUs to whom
such withheld amounts would otherwise have been paid.
Section 7.14 Transfer Taxes. All transfer, documentary, sales, use, stamp,
registration and other such Taxes and fees (including penalties and interest) incurred in
connection with the Offer and Merger shall be paid by Parent and Merger Sub when due, and Parent
and Merger Sub will indemnify the Company and holders of shares of Common Stock, Options and RSUs
against liability for any such Taxes. Parent shall, at its own expense, file all necessary Tax
Returns and other documentation with respect to all such transfer, documentary, sales, use, stamp,
registration and other such Taxes and fees, and, if required by applicable Law, the Company shall
join in the execution of any such Tax Returns and documentation.
ARTICLE VIII
CONDITIONS
CONDITIONS
Section 8.1 Conditions to Each Party’s Obligation to Effect the Merger. The
obligations of the Company, on the one hand, and Parent and Merger Sub, on the other hand, to
consummate the Merger are subject to the satisfaction (or waiver by the Company, Parent and Merger
Sub, if permissible under applicable Law) of each of the following conditions:
(a) Prior to the Effective Time, if required by the DGCL this Agreement shall have been
approved by the Required Company Stockholder Vote and in accordance with the DGCL;
(b) No Governmental Entity having jurisdiction over the Company, Parent or Merger Sub shall
have issued an order, decree or ruling enjoining or otherwise prohibiting consummation of the
Merger or the other Transactions substantially on the terms contemplated by this Agreement;
(c) Any waiting period (and any extension thereof) applicable to the consummation of the
Merger under the HSR Act and any applicable competition, antitrust or investment Laws of
jurisdictions other than the U.S. shall have expired or been terminated;
(d) Merger Sub shall have previously accepted for payment all shares of Common Stock validly
tendered and not withdrawn pursuant to the Offer; provided, however, that this Section
8.1(d) shall not be a condition to the obligation of the Parent or Merger Sub to consummate the
Merger if the failure to satisfy such condition shall arise from the Parent’s or Merger Sub’s
breach of any provision of this Agreement.
Section 8.2 Frustration of Closing Conditions. None of the Company, Parent or Merger
Sub may rely on the failure of any condition set forth in Section 8.1 to be satisfied if
such
43
failure was caused by such party’s failure to act in good faith or use its reasonable best
efforts to consummate the Transactions, as required by and subject to Section 7.8(a).
ARTICLE IX
TERMINATION
TERMINATION
Section 9.1 Termination. Anything herein or elsewhere to the contrary
notwithstanding, this Agreement may be terminated and the Offer, the Merger and the other
Transactions may be abandoned at any time prior to the Effective Time:
(a) by the mutual consent of the Company and Parent;
(b) by either the Company or Parent, upon written notice to the other:
(i) if the Offer Closing shall not have occurred on or prior to January 15,
2011 (the “Termination Date”); provided, however, that the right to
terminate this Agreement under this Section 9.1(b)(i) shall not be available
to any party whose failure to fulfill any obligation under this Agreement has been
the primary cause of the failure of the Offer Closing to occur on or prior to such
date; or
(ii) if any Governmental Entity having jurisdiction over the Company, Parent or
Merger Sub shall have issued an order, decree or ruling or taken any other action,
in each case permanently enjoining or otherwise prohibiting the consummation of the
Merger and the other Transactions substantially as contemplated by this Agreement,
and such order, decree, ruling or other action shall have become final and non
appealable, unless the party seeking to terminate this Agreement pursuant to this
Section 9.1(b)(ii) shall not have complied with its obligations under
Section 7.8(a).
(c) by the Company:
(i) subject to and in accordance with the provisions of Section 7.3; or
(ii) if (A) Merger Sub fails to commence the Offer in violation of Section
2.1 hereof and such breach is not cured within three (3) Business Days following
receipt of written notice of such breach from the Company, (B) the Offer shall have
expired or been terminated without Merger Sub having purchased any shares of Common
Stock pursuant thereto, or (C) Merger Sub, in violation of the terms of this
Agreement, fails to accept for payment and to purchase validly tendered shares of
Common Stock pursuant to the Offer; provided, that the right to terminate this
Agreement pursuant to clause (B) of this Section 9.1(c)(ii) shall not be
available if the Company’s failure to fulfill any covenant or agreement contained in
this Agreement has been the cause of, or resulted in, the Offer having expired or
terminated without Merger Sub having purchased any shares of Common Stock pursuant
thereto.
(d) by Parent:
(i) prior to the Offer Closing, if the Company shall have breached or failed to
perform any of its representations, warranties, covenants or other agreements
contained in this Agreement, which breach or failure to perform (A) would give rise
to the failure of a condition set forth in clauses (v) or (vi) of Exhibit A
and (B)
44
has not been waived by Parent and is incapable of being cured, or is not
cured, by the Company within twenty (20) calendar days following receipt of written
notice of such breach or failure to perform from Parent provided, however, that
Parent shall not have the
right to terminate this Agreement pursuant to this Section 9.1(d)(i) if
Parent or Merger Sub is then in material breach of any of its representations,
warranties, covenants or agreements hereunder;
(ii) at any time prior to the Offer Closing, if on any then scheduled
Expiration Date, Parent is not required to extend the
Offer pursuant to this Agreement and any of the conditions set forth in Exhibit
A shall not have been satisfied; or
(iii) if the Company Board shall have effected a Change of Recommendation
and/or approved or recommended, or proposed publicly to approve or recommend, any
Acquisition Proposal other than this Agreement, and/or permitted the Company to
enter into an Acquisition Agreement related to an Acquisition Proposal prior to the
Offer Closing or the Company shall have failed to include the Company Recommendation
in the Schedule 14D-9 or refused to permit Parent or Merger Sub to include the
Company Recommendation in the Offer Documents or has resolved to take any action
consistent with the foregoing.
Section 9.2 Effect of Termination.
(a) In the event of the termination of this Agreement in accordance with Section 9.1,
written notice thereof shall forthwith be given to the other party or parties specifying the
provision hereof pursuant to which such termination is made, and this Agreement shall forthwith
become null and void (other than Section 9.2, Article X and the last sentence of
Section 7.2), and there shall be no liability on the part of Parent, Merger Sub or the
Company or their respective directors, officers, employees, stockholders, Representatives, agents
or advisors other than, with respect to Parent, Merger Sub and the Company, the obligations
pursuant to this Section 9.2, Article X, and the last sentence of Section
7.2. Nothing contained in this Section 9.2 shall relieve Parent, Merger Sub or the
Company from liability for fraud or willful breach of this Agreement or the Non-Disclosure
Agreement.
(b) In the event that:
(i) this Agreement is terminated by Parent pursuant to Section
9.1(d)(iii); or
(ii) this Agreement is terminated by the Company pursuant to Section
9.1(c)(i);
then the Company shall pay by wire transfer of same day funds to Parent the Company Termination Fee
on the date of termination. Such payment of the Company Termination Fee shall be the sole and
exclusive remedy of Parent and Merger Sub in the case of such termination and, upon payment of such
Company Termination Fee, the Company and its Affiliates shall have no further liability to Parent
or Merger Sub with respect to this Agreement or the Transactions contemplated hereby, provided that
nothing herein shall release any party from liability for willful breach or fraud. “Company
Termination Fee” shall mean an amount equal to One Million Dollars ($1,000,000), plus an
amount equal to an additional Three Hundred Thousand Dollars ($300,000) to reimburse Parent and
Merger Sub for their costs and expenses incurred in connection with this Agreement and the
Transactions.
45
(c) In the event that this Agreement is terminated by the Company pursuant to Section
9.1(c)(ii)(A) or Section 9.1(c)(ii)(C), then the Company may elect to either (i)
pursue any remedy available at Law or in equity, or (ii) require
Parent to pay by wire transfer of same day funds to
the Company the Parent Termination Fee within three (3) Business Days after the Company’s notice
to Parent of such election. In the event that the Company
elects to require Parent to pay the Parent Termination Fee then, upon such election, payment
of the Parent Termination Fee shall be the sole and exclusive remedy of
the Company in the case of such termination and, upon payment of such Parent Termination Fee,
Parent and its Affiliates shall have no further liability to the Company with respect to this
Agreement or the Transactions contemplated hereby, provided, that nothing herein shall release any
party from liability for willful breach or fraud; provided further, in the event Parent fails to
pay the Parent Termination Fee on a timely basis, the Company shall be entitled to pursue any
remedy available at Law or in equity. “Parent Termination Fee” shall mean an amount equal
to One Million Dollars ($1,000,000), plus an amount
equal to an additional Three Hundred Thousand Dollars ($300,000) to reimburse the Company for its
costs and expenses incurred in connection with this Agreement and the Transactions.
(d) In the event that this Agreement is terminated by Parent pursuant to Section
9.1(d)(i), then the Company shall pay by wire transfer of same day funds to Parent, within
three (3) Business Days after Parent’s notice of termination, an amount equal to Three Hundred
Thousand Dollars ($300,000) to reimburse Parent and Merger Sub for their costs and expenses
incurred in connection with this Agreement and the Transactions. Such payment will not be deemed
to limit any other rights or remedies Parent or Merger Sub may have under this Agreement as a
result of such termination.
ARTICLE X
MISCELLANEOUS
MISCELLANEOUS
Section 10.1 Amendment and Modification. Subject to applicable Law, this Agreement
may be amended, modified and supplemented in any and all respects, whether before or after any vote
of the stockholders of the Company contemplated hereby, by written agreement of the parties hereto,
by action taken by their respective boards of directors (or individuals holding similar positions,
in the case of a party that is not a corporation), at any time prior to the Closing Date with
respect to any of the terms contained herein; provided, however, that after the approval of this
Agreement by the stockholders of the Company, no such amendment, modification or supplement shall
reduce or change the Merger Consideration or adversely affect the rights of the Company’s
stockholders hereunder without the approval of such stockholders.
Section 10.2 Nonsurvival of Representations and Warranties. None of the
representations and warranties in this Agreement or in any schedule, instrument or other document
delivered pursuant to this Agreement shall survive the Effective Time or the termination of this
Agreement. This Section 10.2 shall not limit any covenant or agreement contained in this
Agreement that by its terms is to be performed in whole or in part after the Effective Time.
Section 10.3 Notices. All notices, consents and other communications hereunder shall
be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by hand
delivery, by prepaid overnight courier (providing written proof of delivery), by confirmed
facsimile transmission or by certified or registered mail (return receipt requested and first class
postage prepaid), addressed as follows:
46
(a) | if to Parent or Merger Sub, to: | ||
Opto Circuits (India) Ltd. 00, Xxxxxxxxxx Xxxx Xxxxx Xxxx Xxxx Xxxxxxxxx — 560 100 India Facsimile: x00 00 00000000 Attention: Xxxxxx Xxxxxxxx, Director |
with a copy to: |
Xxxxxxx & Xxxxx LLP 00 Xxxx Xxxx, Xxxxx 000 Xxxxxxx, Xxxxxxxxx 00000 Facsimile: (000) 000-0000 Attention: Xxxx Xxxxxxx, Esq. |
(b) | if to the Company, to: |
Cardiac Science Corporation 0000 Xxxxx Xxxxx Xxxxxxx Xxxxxxx, Xxxxxxxxxx 00000 Facsimile: (000) 000-0000 Attention: Xxxxx X. Xxxxxx |
with a copy to: |
Xxxxxxx Coie LLP 0000 Xxxxx Xxxxxx, Xxxxx 0000 Xxxxxxx, Xxxxxxxxxx 00000 Facsimile: 000-000-0000 Attention: Xxxxxxx X. Xxxxxxxxx, Esq. |
Xxxx X. XxXxxx, Esq. |
or to such other address or facsimile number for a party as shall be specified in a notice given in
accordance with this section; provided that any notice received by facsimile transmission or
otherwise at the addressee’s location on any Business Day after 5:00 P.M. (addressee’s local time)
shall be deemed to have been received at 9:00 A.M. (addressee’s local time) on the next Business
Day; provided further that notice of any change to the address or any of the other details
specified in or pursuant to this section shall not be deemed to have been received until, and shall
be deemed to have been received upon, the later of the date specified in such notice or the date
that is five (5) Business Days after such notice would otherwise be deemed to have been received
pursuant to this section. A party’s rejection or other refusal to accept notice hereunder or the
inability of another party to deliver notice to such party because of such party’s changed address
or facsimile number of which no notice was given by such party shall be deemed to be receipt of the
notice by such party as of the date of such rejection, refusal or inability to deliver. Nothing in
this section shall be deemed to constitute consent to the manner or address for service of process
in connection with any legal proceeding, including litigation arising out of or in connection with
this Agreement.
47
Section 10.4 Interpretation. The parties have participated jointly in the negotiation
and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption
or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any
provisions of this Agreement. Information provided in any section of the Company Disclosure
Schedule or Parent Disclosure Schedule shall be deemed to be adequate response and disclosure of
such facts or circumstances with respect to any section of Article V calling for disclosure
of such information, whether or not such disclosure is specifically associated with or purports to
respond to one or more or all of such representations or warranties; provided that the inclusion of
such information in another section would be reasonably apparent. The inclusion of any item in the
Company Disclosure Schedule shall not be deemed to be an admission or evidence of materiality of
such item, nor shall it establish any standard of materiality for any purpose whatsoever.
Section 10.5 Counterparts. This Agreement may be executed in multiple counterparts,
each of which when executed and delivered shall be deemed to be an original but all of which taken
together shall constitute one and the same agreement.
Section 10.6 Entire Agreement; Third-Party Beneficiaries. This Agreement (including
the Company Disclosure Schedule, the Parent Disclosure Schedule and the exhibits and instruments
referred to herein) and the Non-Disclosure Agreement (a) constitute the entire agreement and
supersede all prior agreements and understandings, both written and oral, among the parties with
respect to the subject matter hereof and (b) except for (i) the provisions set forth in Section
7.6 of this Agreement, (ii) the right of the Company’s stockholders to receive the Merger
Consideration in accordance with Section 4.2(b), and (iii) the right of the holders of
Options or RSUs to receive the Option Consideration or RSU Consideration, as applicable, in
accordance with Section 3.4(a) and Section 3.4(b), respectively shall not benefit
any third party.
Section 10.7 Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction or other authority to be invalid, void,
unenforceable or against its regulatory policy, the remainder of the terms, provisions, covenants
and restrictions of this Agreement shall remain in full force and effect and shall in no way be
affected, impaired or invalidated.
Section 10.8 Governing Law; Venue.
(a) This Agreement shall be governed and construed in accordance with the laws of the State of
Delaware applicable to contracts to be made and performed entirely therein without giving effect to
the principles of conflicts of law thereof or of any other jurisdiction.
(b) Each of the parties hereto hereby (i) expressly and irrevocably submits to the exclusive
personal jurisdiction of any United States federal court located in the State of Delaware or any
Delaware state court in the event any dispute arises out of this Agreement or any of the
Transactions, (ii) agrees that it will not attempt to deny or defeat such personal jurisdiction by
motion or other request for leave from any such court and (iii) agrees that it will not bring any
action relating to this Agreement or any of the Transactions in any court other than a United
States federal or state court sitting in the State of Delaware; provided that each of the parties
shall have the right to bring any action or proceeding for enforcement of a judgment entered by any
United States federal court located in the State of Delaware or any Delaware state court in any
other court or jurisdiction.
(c) Each party irrevocably consents to the service of process outside the territorial
jurisdiction of the courts referred to in Section 10.8(b) in any such action or proceeding
by
48
mailing copies thereof by registered United States mail, postage prepaid, return receipt
requested, to its address as specified in or pursuant to Section 10.3. However, the
foregoing shall not limit the right of a party to effect service of process on the other party by
any other legally available method.
Section 10.9 Specific Performance. Each of the parties hereto acknowledges and agrees
that, in the event of any breach of this Agreement, each nonbreaching party would be irreparably
and immediately harmed and could not be made whole by monetary damages. It is accordingly agreed
that the parties hereto (a) will waive, in any action for specific performance, the defense of
adequacy of a remedy at law and (b) shall be entitled, in addition to any other remedy to which
they may be entitled at law or in equity, to compel specific performance of this Agreement in any
action instituted hereunder without bond or other security being required.
Section 10.10 Assignment. Neither this Agreement nor any of the rights, interests or
obligations hereunder shall be assigned by any of the parties hereto (whether by operation of law
or otherwise) without the prior written consent of the other parties. Subject to the preceding
sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by the
parties and their respective permitted successors and assigns. Any purported assignment hereof not
in compliance with this Section 10.10 shall be null and void.
Section 10.11 Expenses. All costs and expenses incurred in connection with the
Merger, this Agreement and the consummation of the Transactions shall be paid by the party
incurring such costs and expenses, whether or not the Merger or any of the other Transactions is
consummated.
Section 10.12 Headings. Headings of the articles and sections of this Agreement and
the table of contents, schedules and exhibits are for convenience of the parties only and shall be
given no substantive or interpretative effect whatsoever.
Section 10.13 Waivers. Except as otherwise provided in this Agreement, any failure of
any of the parties to comply with any obligation, covenant, agreement or condition herein may be
waived by the party or parties entitled to the benefits thereof only by a written instrument signed
by the party granting such waiver, but such waiver or failure to insist upon strict compliance with
such obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel
with respect to, any subsequent or other failure.
Section 10.14 Waiver of Jury Trial. EACH OF PARENT, MERGER SUB AND THE COMPANY HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER
BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS
OF PARENT, MERGER SUB OR THE COMPANY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND
ENFORCEMENT THEREOF.
[Remainder of page intentionally left blank.]
49
IN WITNESS WHEREOF, the Company, Parent and Merger Sub have caused this Agreement to be signed
by their respective officers thereunto duly authorized as of the date first written above.
CARDIAC SCIENCE CORPORATION as Company |
||||||
By: | /s/ XXXXX X. XXXXXX | |||||
Title: CEO & President | ||||||
OPTO CIRCUITS (INDIA) LTD. as Parent |
||||||
By: | /s/ XXXXX XXXXXXX | |||||
Title: Chairman & Managing Director | ||||||
JOLT ACQUISITION COMPANY as Merger Sub |
||||||
By: | /s/ XXXXXX VASWANEY | |||||
Title: President |
EXHIBIT A
CONDITIONS OF THE OFFER
Notwithstanding any other provisions of the Offer, Merger Sub shall not be required to, and
Parent shall not be required to cause Merger Sub to, accept for payment or, subject to any
applicable rules and regulations of the SEC, including Rule 14e-1(c) under the Exchange Act, pay
for any tendered shares of Common Stock unless:
(i) | There shall have been validly tendered and not validly withdrawn prior to the expiration date for the Offer (as it may have been extended or re-extended pursuant to the Agreement, the “Expiration Date”) that number of shares of Common Stock which, when added to the shares of Common Stock already owned by Parent and its Subsidiaries including Merger Sub, represents the greater of (x) at least a majority of the total number of outstanding shares of Common Stock on a fully diluted basis (which assumes conversion or exercise of all outstanding Options, or any other rights, options or warrants to acquire Common Stock or (y) at least sixty percent (60%) of the issued and outstanding shares of Common Stock (for purposes hereof, the greater of such threshold shall be referred to herein as the “Minimum Tender Condition”); | ||
(ii) | Any waiting period (and any extension thereof) applicable to the consummation of the Offer under the HSR Act and any applicable competition, antitrust or investment Laws of jurisdictions other than the U.S. shall have expired or been terminated; | ||
(iii) | No applicable Law and no permanent injunction or other judgment, order or decree entered, promulgated, enforced or issued by any court or other Governmental Entity of competent jurisdiction in the U.S. or any material foreign jurisdiction shall be and remain in effect which has the effect of making illegal or otherwise prohibiting the consummation of the Offer or any of the other Transactions, or imposes any material limitations on Parent’s ownership of the Company, or operation of all or a material portion of Parent’s, on the one hand, or the Company’s, on the other hand, businesses or assets or compels Parent or the Company or Parent’s Subsidiaries to dispose of or hold separate any material portion of the respective businesses or assets of Parent or the Company; | ||
(iv) | There shall not then be pending any action, litigation or proceeding by any Governmental Entity that would reasonably be expected to result in any of the consequences referred to in subparagraph (ii) above; | ||
(v) | The representations and warranties of the Company contained in this Agreement and in the certificate delivered by the Company pursuant to subparagraph (vi) below (disregarding for purposes of this subparagraph (iv), any materiality or Company Material Adverse Effect qualifications contained in such representations and warranties) |
shall be true and correct in all respects both as of the date of the Agreement and as of the Offer Closing Date as though made on and as of the Offer Closing Date (except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall be true and correct in all respects on and as of such earlier date), except where the failure of any such representations or warranties to be so true and correct would not, individually or in the aggregate, have, or reasonably be expected to have, a Company Material Adverse Effect; | |||
(vi) | The Company shall have performed in all material respects all obligations required to be performed by it under the Agreement at or prior to the Offer Closing Date; | ||
(vii) | The Company shall have delivered to Parent a certificate, signed by the chief executive officer and chief financial officer of the Company, to the effect that each of the conditions specified in subparagraphs (iv) and (v) above is satisfied; | ||
(viii) | The Company and Parent shall not have reached an agreement that the Offer or the Agreement be terminated, and the Agreement shall not have been terminated in accordance with its terms; and | ||
(ix) | There shall not have occurred any event or condition that has had a Company Material Adverse Effect. |
The foregoing conditions shall be in addition to, and not a limitation of, the rights of
Parent and Merger Sub to extend, terminate and/or modify the Offer pursuant to the terms of the
Agreement.
The foregoing conditions are for the benefit of Parent and Merger Sub, may be asserted by
Parent or Merger Sub regardless of the circumstances giving rise to any such conditions and may be
waived by Parent or Merger Sub in whole or in part at any time and from time to time in their sole
discretion (except for the Minimum Tender Condition (defined herein)), in each case, subject to the
terms of the Agreement and the applicable rules and regulations of the SEC. The failure by Parent
or Merger Sub at any time to exercise any of the foregoing rights shall not be deemed a waiver of
any such right and each such right shall be deemed an ongoing right which may be asserted at any
time and from time to time.